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[On the case of Isak van Halmaal, who:]  
 
“… in the beginning of the summer season, was afflicted with a severe 
headache, occurring and disappearing daily on fixed hours, with such an 
intensity that he often assured me that he could not bear the pain 
anymore or he would succumb shortly. For rarely, it lasted more than two 
hours. And the rest of the day there was no fever, nor indisposition of the 
urine, nor any infirmity of the pulse. But this recurring pain lasted until the 
fourteenth day..” 
 
                                               Nicolaes Tulp, Observationes Medicae,1641 
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ACV   Average constriction velocity 
ADV   Average dilation velocity 
ASPS            Advanced Sleep Phase Syndrome 
CGRP           Calcitonine gene-related peptide 
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CNS   Central nervous system 
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Klasehodepine er en primær hodepine med en slående periodisk opptreden.  
Mange har derfor påpekt at klasehodepine må være en kronobiologisk 
lidelse, og at den biologiske klokka er involvert i patofysiologien. Få studier 
har undersøkt dette i detalj.  
I denne avhandlingen har vi studert flere aspekter ved kronobiologi hos 
klasehodepinepasienter. I den første studien kartla vi periodisk opptreden av 
hodepine, forekomst av søvnforstyrrelser og skiftarbeid i en 
klasehodepinepopulasjon nord for polarsirkelen. Dette er en geografisk 
region med ekstreme forskjeller i lysforhold gjennom året. Vi fant at periodisk 
opptreden av hodepine var den samme her som i andre 
klasehodepinepopulasjoner. I tillegg fant vi en høy forekomst av kronisk 
insomni og skiftarbeid blant pasientene.  
Dernest undersøkte vi en variable number tandem repeat (VNTR) sekvens i 
klokkegenet PERIOD3 hos klasehodepinepasienter. Dette er en 
polymorfisme som har vist seg å korrelere med foretrukket døgnrytme 
(kronotype) i flere friske populasjoner. Vi kartla også kronotype hos en 
undergruppe av pasientene ved hjelp av validerte spørreskjema. 
Sammenlignet med en tidligere publisert frisk, norsk kontrollgruppe, fant vi 
ingen forskjell i PERIOD3 VNTR polymorfisme. Vi fant heller ingen sikre 
avvik i kronotyper.  
I den tredje studien undersøkte vi kranial autonom funksjon i remisjonsfasen 
av klasehodepine. Vi gjorde pupillometri av lysrefleksen, målte tykkelsen av 
a. temporalis superficialis og tykkelsen av retinale kar ved hjelp av 
standardiserte metoder hos 30 klasehodepinepasienter. Sammenlignet med 
kontroller fant vi signifikant redusert parasympatisk respons i pupillens 
lysrefleks på begge øyne, mer uttalt på den symptomatiske siden. De retinale 
venene var også signifikant tynnere på symptomatisk side sammenlignet 
med asymptomatisk side, muligens på grunn av redusert parasympatisk 
tonus. Funnene antyder en sentral årsak til klasehodepine, og vi lanserer en 




Cluster headache has been claimed to be a chronobiological disorder 
because of its striking periodic occurrence. This suggests that the biological 
clock is involved in the pathophysiology of the disease, but few researchers 
have studied this in depth. 
In this thesis, we have studied several aspects of chronobiology in cluster 
headache patients. First, we assessed the periodicity of headache attacks, 
the frequency of sleep disturbances and shift work employment in a cluster 
headache population living north of the Arctic Circle, a region with extreme 
variations in external light. We found that the periodicity of headache was the 
same here as in other cluster headache populations, but we also found a 
high frequency of chronic insomnia and shift work occupation among the 
patients.  
Second, we sequenced a variable number tandem repeat DNA-sequence of 
the clock gene PERIOD3 in cluster headache patients. This is a core clock 
gene mutation known to be associated with preferred daily rhythm in healthy 
populations. A subpopulation of patients were also chronotyped, meaning 
that we assessed their preferred daily rhythms through validated 
questionnaires. Compared to a healthy population of Norwegian students, 
there was no difference in PERIOD3 genotype distribution. We also did not 
find certain deviations in chronotypes.  
Finally, we studied cranial autonomic function in the remission phase of 
cluster headache. Thirty patients were examined in their headache-free 
period, undergoing light-reflex pupillometry, ultrasound measurement of the 
superficial temporal artery diameter and computer-assisted retinal vessel 
caliber measurements of both eyes. We found a significantly reduced 
parasympathetic response in the pupillary light reflex on both eyes, more 
pronounced on the symptomatic side, compared to controls. The retinal veins 
were also smaller on the symptomatic side compared to the asymptomatic 
side, possibly caused by reduced cranial parasympathetic tone. The findings 
suggest a central origin of the disease, and we propose a theory of 
hypothalamic involvement in cluster headache pathophysiology.  
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Cluster headache (CH) is a relatively rare, but severe form of primary 
headache, affecting between 0,05- 0,5% of the population (1). It is 
characterized by recurring episodes of intense, unilateral pain, accompanied 
by ipsilateral cranial autonomic symptoms such as conjunctival injection, 
lacrimation, miosis and ptosis (2). Headache attacks and bouts often occur in 
a striking periodic pattern, waking the patient from sleep at the same time 
every night (3). This cyclic behavior has prompted the theory that cluster 
headache is a chronobiological disorder, and that the pathophysiology may 
be associated to the hypothalamic biological clock (4). Several studies have 
examined the periodic patterns of cluster headache in different populations, 
but few have studied the biological clock itself. 
The pathophysiology of CH is largely unknown, but like migraine it was long 
regarded as a peripheral, vascular headache, linked to changes in cranial 
vascular tone, and possibly reduced venous drainage from the cavernous 
sinus (5). However, as in migraine, increased knowledge of the 
hypothalamus and central structures involved in pain processing have turned 
the focus of interest from the peripheral to the central nervous system (CNS). 
Based on the findings in several interesting studies on neuroendocrinology, 
neuroimaging and the autonomic nervous system, the majority of the 
scientific community now believe that the origin of disease must lie within the 
CNS. 
The work in this thesis was motivated by the need for further knowledge on 
the connection between chronobiology, the autonomic nervous system and 










2.1 Clinical Characteristics of cluster headache 
CH is an episodic headache, with repeated attacks that last between 15 to 
180 minutes, up to eight times per day (2). The pain is located in the 
innervation area of the 1st branch of the trigeminal nerve and is strictly 
unilateral, although it may switch sides between headache bouts in 14-18% 
of patients (3, 6). The condition is said to be extremely painful, allegedly 
comparable to renal stones or childbirth. The intense pain is often described 
as “sharp”, “piercing” or “burning”, and has earned CH the nickname of 
“suicide headache”. In an internet-based survey from the U.S. of 1134 CH 
patients, 55% had contemplated suicide, and two percent had actually tried 
to end their own lives (7). Frequently reported triggers for attacks include 
small quantities of alcohol, nitrates such as nitroglycerine, and (nocturnal) 
sleep (6, 7). 
The name cluster headache refers to the fact that attacks occur in bouts or 
clusters that usually last from one week up to three months, after which the 
headache disappears for at least one month. About 70% of patients have one 
or two bouts per year (8). In a British series, one bout lasted on average 8,6 
weeks (3). About 10% of patients have chronic cluster headache, meaning 
that there are no pauses between bouts (9). The condition was originally 
named Hortons headache after Bayard Taylor Horton, who in 1939 published 
a complete description and a theory of pathogenesis for the condition (10), 
but clinical descriptions of the syndrome are known dating as far back as the 
17th century (11). 
During attacks, patients may have autonomic symptoms in the form of miosis 
and ptosis on the symptomatic side, as well as ipsilateral conjunctival 
injection, lacrimation, nasal congestion or rhinorrhea, edema of the eyelid 
and sweating of the forehead or face. The International Classification of 
Headache Disorders (ICHD) classifies CH as one of the Trigeminal 
Autonomic Cephalagias (TACs), a group of primary headaches that resemble 
each other because of the combination of headache and cranial autonomic 
symptoms. The patients are often restless or agitated, unable to lie down or 
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rest. Migrainous features such as photo- and phonophobia, nausea, vomiting 
and visual or sensory auras may occur in up to 20% of patients (7). 
2.2 Prevalence, diagnosis and predisposing factors 
The incidence of CH is unknown, but the prevalence varies from 0.05% to 
0.5% in different studies (1). In a Norwegian study from 2003, authors 
Sjaastad and Bakketeig interviewed 1838 inhabitants between the age of 18 
and 65 years in the municipality of Vågå, Norway, and found seven (0.38%) 
that met the diagnostic criteria of CH (12). Unlike migraine, which has a 
female predominance, CH affects men 3 to 4 times as often as women (13). 
Onset is usually between the ages of 20 to 40 years, but CH has been 
diagnosed in patients as young as 4 and as old as 96 years of age (9). The 
diagnosis is made by a thorough medical history, evaluating the symptoms 
and signs in accordance to the criteria set by the ICHD (Box 1).  
Despite the characteristic presentation of the disease and the intensity of the 
symptoms, time to correct diagnosis is persistently long, up to six years in 
some studies (14). Secondary forms are mainly caused by carotid dissection 
or tumors in the sellar/parasellar region, and should be ruled out (15). 
CH seldom runs in families, but about five percent of patients report that they 
have relatives who are also diagnosed with the condition (3). When 
compared to the general population, first-degree relatives of CH patients 
have a 5-18 times higher risk of being affected, and second-degree relatives 
a 1-3 times higher risk (16). A genetic predisposition in CH is likely, but there 
are probably multiple genes and environmental factors involved and the 
mode of inheritance is uncertain. Studies of CH in families and twins have 
shown a probable autosomal dominant inheritance with low penetrance in 
some families, and autosomal recessive or multifactorial inheritance in others 
(16). An association has been made with the alcohol dehydrogenase gene 
and a novel rearrangement involving the intron-region of the neurexin 3 gene 
(17), but the findings should be confirmed in larger populations. A missense 
single nucleotide polymorphism of the hypocretine receptor 2 gene has also 
been associated to CH in several studies, but a recent meta-analysis casts 
doubt on these findings (18).  
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About 30% of CH patients report of a family history of migraine (3), but they 
do not have more co-morbid migraine than the general population (19). A 
high prevalence of smokers seem to be a consistent finding in population 
studies of CH (9), reporting up to 80% of patients as current or previous 
smokers (6).  However, quitting tobacco does not alter the clinical course of 
the disease, which indicates that there is no causal link between the two (20). 
Historically, CH patients were characterized, and to some degree 
Diagnostic criteria for cluster headache: 
A. At least 5 attacks fulfilling criteria B-D 
B. Severe or very severe unilateral orbital, supraorbital and/or temporal pain 
lasting 15-180 minutes (when untreated) 
C. Either or both of the following:  
a. At least one of the following symptoms or signs, ipsilateral to the 
headache: 
i. Conjunctival injection and/or lacrimation 
ii. Nasal congestion and/or rhinorrhoea 
iii. Eyelid oedema 
iv. Forehead and facial sweating 
v. Forehead and facial flushing 
vi. Sensation of fullness in the ear 
vii. Miosis and/or ptosis 
b. A sense of restlessness or agitation  
D. Attacks have a frequency between one every other day and eight per day for 
more than half of the time when the disorder is active 
E. Not better accounted for by another ICDH-3 diagnosis 
Episodic cluster headache: Attacks occur in periods lasting from seven days to one 
year, separated by pain-free periods lasting at least one month.  
Chronic cluster headache: Attacks occur for more than 1 year without remission, 
or with remission periods lasting less than 1 month.  
 
 





stigmatized, as the prototypical “testosterone male” in both appearance and 
behavior: ambitious, hard-working, and a heavy user of tobacco and alcohol 
(21). Admittedly, alcohol is one of the most frequently cited triggers for CH 
attacks (7), but so far there is no documentation of a higher alcohol 
consumption in CH populations.  
2.3 Treatment  
Medical treatment in CH can be divided in to three categories: acute 
treatment, preventive treatment and “bridging”. According to the European 
Federation of Neurological Societies, first-line treatment of CH attacks is 
inhalation of 100% Oxygen 12-15 L/min via mask, or a subcutaneous 
injection of 6 mg Sumatriptan (22). For preventive treatment, the drug of 
choice is Verapamil, but Lithium and Topiramate may also be used. 
Methysergide is also listed as a second drug of choice, but has potentially 
serious side effects and is not available in many countries, including Norway. 
A transitional treatment (“bridging”) of steroids, administered orally or 
intravenously, may be given to shorten the CH bouts and ease the burden of 
headache attacks before the effect of the initiated preventive treatment has 
kicked in (23). In chronic, refractory CH, several surgical interventions have 
been used through the years with varying success. For the last decade, 
neuromodulation strategies such as electrical stimulation of the occipital 
nerves, sphenopalatine ganglion, or even deep brain stimulation have grown 
into more promising alternatives (24). A detailed presentation of CH 
treatment is beyond the scope of this thesis. For further information, please 
see the references given in this section.  
2.4 Periodicity of cluster headache 
CH has a striking periodic occurrence. In up to 80% of patients, headache 
attacks occur at the same time each day (7, 25). About half of the patients 
have two or fewer attacks a day. More than 70% report predictability of attack 
onset at night, waking them from sleep (3). The most frequent time of the day 
to have a CH attack seems to be around 2 a.m., although a previous 
Norwegian study found a peak incidence between 4 and 7 a.m. (26), and an 
Italian study found a peak incidence between 1 and 3 p.m., coinciding with 
the southern European time of siesta (8). The observed tendency of CH 
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attacks to occur during sleep or resting states have made researchers 
propose that CH attacks are initiated in a state of hypoarousability (27). 
Similar to diurnal predictability of CH attacks, up to 43% of patients also 
report that CH bouts occur at predictable times of year (3). Most patients 
have one or two bouts per year, but when it comes to the timing of bouts, the 
results of different studies are diverging. In an American study from 1987, CH 
bouts started most often in January and July (28), a finding that the author 
connected to summer and winter solstices, suggesting that the initiation of 
bouts was related to the length of the photoperiod. However, in two other 
studies bouts were most likely to begin in spring and autumn, closer to the 
equinoxes (3, 7). A Danish study did not find a biphasic pattern in the annual 
rhythmicity of CH attacks, but a clear reduction of attack frequency in the 
summer, which gave a statistically significant inverse relation between attack 
frequency and the number of daylight hours (29).  
2.5 Sleep in cluster headache 
Sleep disturbances are frequent in all headache populations, but there 
seems to be a special relationship between sleep and CH (30, 31). The 
International Classification of Sleep Disorders classifies CH as a sleep-
related headache, together with hypnic headache, chronic paroxysmal 
hemicranias and migraine (32). As noted, most CH attacks occur at night, 
and sleep seem to be one of the most frequent triggers for attacks (29). CH 
patients score significantly lower on sleep quality measures compared to 
healthy controls, and continue to do so as long as one year after the last 
attack, which indicates that it is not merely the nocturnal headache attacks 
that cause the sleep disturbances. In early studies of sleep and CH, attacks 
seemed to be related to REM-sleep stages (33, 34), but the number of 
patients included in these studies was small, and the results somewhat 
conflicting. Two previous open-label studies and one controlled study have 
also suggested that the prevalence of sleep-disordered breathing is high in 
CH populations (35-37). There is no doubt that a complex anatomical and 
physiological overlap exists between headache and sleep disorders, 
suggesting a common pathophysiology. Increasing evidence point at the 
importance of diagnosing and treating the two combined (38).  
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3  Pathophysiology 
  
The combination of unilateral headache and cranial autonomic symptoms 
makes CH an interesting disorder to study in view of headache 
pathophysiology. The central theory of CH pathophysiology grew out of a 
combination of clinical observations and pathophysiological studies, in which 
a strict peripheral theory of activation proved inadequate. Reported cases of 
patients continuing to have CH attacks after rhizotomy of peripheral nerves or 
ganglions (e.g. the trigeminal nerve), headache side shifts between bouts, 
and continued attacks of autonomic symptoms after the pain had been 
successfully treated, suggested a primary involvement of the CNS in CH 
pathophysiology (39). The hypothalamus early became the center of 
attention, as this small area of the brain is involved in both pain processing, 
autonomic function, and neuroendocrine secretion (40). It is also the location 
of the master circadian clock (the suprachiasmatic nucleus, SCN), which 
controls the biological rhythms of the body including the sleep-wake cycle. 
Due to the clock-like regularity of CH, the SCN has been proposed as the 
generator of attacks, but so far there is no pathophysiological model 
explaining how this generation might occur.  
During attacks, the autonomic symptoms observed seem to be caused both 
by a hyperactivity of parasympathetic neurons (conjunctival injection, tearing 
and nasal congestion/rhinorrhea), and a hypoactivity of oculosympathetic 
neurons (miosis and ptosis). The mechanisms underlying these symptoms 
are only partly known. In the following, I will summarize the current 
knowledge and theories of CH pathophysiology. 
3.1 Predisposition and initiation of attacks: The hypothalamus 
Several neuroendocrine studies have implicated involvement of the 
hypothalamus in CH pathophysiology. The SCN regulates secretion of 
melatonin, a sleep hormone secreted by the pineal gland, and studies have 
shown that the nocturnal peak of melatonin is blunted in CH patients in active 
bout (41). In addition, the excretion of the melatonin metabolite in urine is 
abnormal, both in cluster bout and in remission phase (42). Studies have also 
documented abnormal levels of several hormones connected to the 
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hypothalamic-pituitary axis in CH, including cortisol, testosterone, prolactin 
and growth hormone (43). All of these hormones are normally secreted with a 
circadian rhythmicity, run by the SCN. However, neuroendocrine changes 
may not be specific to CH, as disturbances are also documented in other 
disorders such as migraine, fibromyalgia, chronic fatigue syndrome and 
irritable bowel syndrome (44). 
One early structural imaging study found increased grey matter in the 
posterior inferior hypothalamus in CH patients, using the method of voxel-
based morphometry of the brain (45). However, later studies have not been 
able to reproduce the finding (46, 47). Functional imaging studies using PET 
and fMRI have repeatedly shown activation of the posterior hypothalamic 
grey matter during both spontaneous and experimentally induced CH attacks 
(48-51), an activation pattern initially believed to be specific to the condition. 
However, a more recent study of spontaneous migraine attacks also showed 
activation of hypothalamic regions (52). The spatial resolution is a limitation 
to such studies, and several authors have pointed out that the activation 
pattern of the studies may not be in the hypothalamus itself, but in the 
midbrain tegmentum, slightly posterior and inferior to the hypothalamus (53). 
Deep brain stimulation directed at the posterior hypothalamus seems to be a 
promising treatment for intractable chronic CH patients, although not without 
risks (24). The effect of the treatment is often delayed up to six months, 
which may point at a pain modulating, rather than a direct causative effect.  
The hypothalamus is undoubtedly involved in CH, but whether it is pivotal in 
causing the attacks, or merely a part of a larger pain matrix, is still unclear 
(44).  
3.2 The pain in CH attacks 
The pain in CH is conducted by the 1st branch of the trigeminal nerve (fifth 
cranial nerve). This nerve carries afferent nociceptive fibers from the dura 
mater and cranial blood vessels. A well-described neurovascular reflex arc is 
activated, called the trigeminoparasympathetic or trigeminovcascular reflex 
(Figure 1) (54). This reflex causes trigeminal pain combined with 
parasympathetic efflux, and may be triggered by painful stimulation of the 
eyes, mouth, nose or facial skin (40). The trigeminal neurons ascend to the 
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trigeminocervical complex in the caudal trigeminal nucleus, where they meet 
with the afferent cervical nerves of C1 and C2. The neurons synapse and 
project to the thalamus where they synapse again and proceed to various 
cortical areas, leading to pain.  
The trigeminal neurons contain several powerful vasodilators: Calcitonine 
Gene-Related Peptide (CGRP), Substance P (SP) and Neurokinin A (NKA) 
(54). CGRP is the most powerful vasodilator in the cerebral circulation. In 
addition, increased levels of Vasoactive Intestinal Peptide (VIP) has been 
found both during spontaneous CH attacks (55) and nitroglycerine-induced 
attacks (56). VIP is a marker for parasympathetic activity. Reports of CH 
patients that describes typical CH pain attacks with no accompanying 
autonomic symptoms, or attacks with autonomic symptoms but no pain (57, 
58), suggest that the reflex is not always activated, and it is unclear how the 
pain is initiated. The attacks often end as abruptly as they begin, and what 
terminates the attack is also unknown.  
3.3 Symptoms of parasympathetic hyperactivity: Lacrimation, rhinorrhea, 
conjunctival injection, and flushing 
About 90% of CH patients report of ipsilateral lacrimation during attacks, and 
about 75% report conjunctival injection, nasal congestion or rhinorrhea (3, 7-
9). The nociceptive input from the trigeminal nerve leads to a reflex activation 
of the rostral superior salivary nucleus (SSN) via the posterior hypothalamic 
grey matter (40). The parasympathetic fibers from this nucleus exit the scull 
in the intermediate nerve, along with the facial nerve (seventh cranial nerve), 
and project to the geniculate ganglion where they leave the facial nerve and 
form the greater superficial petrosal nerve. The fibers synapse in the 
sphenopalatine (pterygopalatine) ganglion, creating postganglionic neurons 
that project to the target organs (Figure 1). Activation causes lacrimation from 
the lacrimation glands, secretion from the nasopalatine mucosa, and cranial 







Figure 1: The trigeminoparasympathetic reflex arc. Incoming noxious stimuli from the 
1st trigeminal branch and upper cervical afferents ascend to the trigeminocervical 
complex, where they synapse and project to the thalamus. Here they synapse again 
and proceed to the cortex, leading to perceived pain. A reflex activation of the superior 
salivary nucleus produces parasympathetic efflux, leading to secretion from the 
lacrimation glands and nasopalatine mucosa, and vasodilation of choroidal and 
cranial vessels. Several powerful vasodilators are secreted by the trigeminal neurons.  
 
Dilation of the ipsilateral ophthalmic artery during cluster attacks has been 
documented in angiographic studies (59, 60), and transcranial Doppler 
investigations have shown a reduction of blood flow velocity in the ipsilateral 
middle cerebral artery, also indicating vasodilation (61). In a study of nine CH 
patients where the luminal diameters of the superficial temporal arteries was 
measured both during and in between attacks, the investigators found no 
asymmetry between the headache side and the asymptomatic side in the 
pain free state, but a significant reduction of the luminal diameter on the 
asymptomatic side during attacks (62). The authors interpreted this finding as 
a result of a general, pain-induced arterial vasoconstriction during attacks, 
which was opposed by the trigeminoparasympathetic activation on the 
headache side, causing a relative ipsilateral vasodilation. As mentioned, 
several powerful vasodilators have been detected in the blood stream during 
CH attacks, but some of the vasodilatory response may also be caused by a 
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reduction of ipsilateral sympathetic vascular tone (63). The attack-related 
parasympathetic discharge may also contribute to the rapid escalation of 
pain. 
However, whereas parasympathetic activation normally includes salivation, 
increased salivation is not a feature in CH. This fact has previously been a 
topic of debate among researchers. In my opinion, the organization of the 
SSN may explain this, as the SSN consists of two separate groups of 
neurons (64). One group is located in the rostral ventrolateral region of the 
SSN and sends projections to the lacrimal glands, the nasopalatine mucosa 
and the cerebral and choroidal vasculature. The other group of neurons lies 
in the caudal and dorsolateral region and projects to the submandibular and 
sublingual salivatory glands. Activation of the trigeminoparasympathetic 
reflex in CH may involve only the former of these.  
3.4 Symptoms of sympathetic hypoactivity: Miosis and ptosis 
Ipsilateral ptosis during attacks is reported in about 75% of patients, whereas 
miosis is reported in about 40% (3, 7-9). The combination of the two is often 
referred to as a partial Horner syndrome. A subgroup of patients has 
persistent signs of such oculosympathetic dysfunction between attacks, or 
even in remission phase. The course of the oculosympathetic fibers are 
complex and not fully understood, but the efferent neurons seem to originate 
in three nuclei of the posteriolateral hypothalamus: the parvicellular part of 
the paraventricular nucleus (PVN), the dorsal part of the lateral hypothalamic 
nucleus, and the posterior hypothalamic nucleus (Figure 2) (65). The neurons 
project to the intermediolateral column in the upper spinal cord, from which 
preganglionic sympathetic neurons run to the superior cervical ganglion 
(SCG). Most of the sympathetic fibers to the pupil leave the spinal cord at the 
level of TH1, whereas vasomotor and sudomotor fibers to the face leave at 
level TH2-3 (63). From the SCG, postganglionic neurons to the eyes and the 
forehead form a plexus around the internal carotid artery (ICA), following the 
artery into the petrous segment of the carotid canal. From here, they project 
uninterrupted to the pupil dilator muscle in the eye and to the sweat glands in 
a small area of the medial forehead, causing pupillary dilation and forehead 
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sweating. The sympathetic neurons innervating the sweat glands in the lower 






Figure 2: The oculosympathetic pathway. Light evoked impulses are carried from the 
retina to hypothalamus via the retinohypothalamic pathway. Dilation of the pupil is 
caused by oculosympathetic fibers originating from the paraventricular nucleus 
(PVN), the lateral hypothalamic nucleus and the posterior hypothalamic nucleus. 
These fibers project to the intermediolateral column, where they synapse and go to 
the superior cervical ganglion. From here, the third order sympathetic fibers form a 
plexus around the internal carotid artery, before reaching the iris dilator muscle. The 
figure also shows how the connections between the trigeminocervical complex and 
the PVN, the periaqueductal grey and the locus coeruleus, which may all be involved 







Several studies have assessed the pupillary responses to topically induced 
pharmaceuticals acting on the autonomic pathways in the eyes of CH 
patients. Most of these studies, but not all, have found an ipsilateral 
oculosympathetic dysfunction similar to a third order Horner syndrome (63). 
Fanciullacci et al. tested 45 CH patients, using the contralateral eye as 
control, and found a significantly reduced pupillary dilation response to 
Tyramine, Cocaine and Homatotropine on the headache-affected side, 
consistent with a third order oculosympathetic defect (66). However, they did 
not find a supersensitivity reaction to Phenylepinephrine as one would expect 
in a proper Horner syndrome. Salvesen et al. found a significantly reduced 
dilation response to the sympathomimetic Hydroxyamphetamine, but not 
Tyramine, in 32 CH patients compared to healthy controls, but they did find a 
weak supersensitivity reaction to Phenylepinephrine on the headache-
affected side (67). The authors found the results most compatible with a third 
order Horner syndrome, but pointed out that the lesion could not be 
complete, and that such moderate reactions also could be seen in central 
lesions.  
The current pathophysiological hypothesis explaining the apparent third order 
sympathetic lesion in CH came from a case report from 1970, where a CH 
patient had an unexpected attack during carotid angiography (59).  The 
angiogram showed a localized narrowing of the ipsilateral extracranial part of 
the ICA, which 15 minutes later had progressed further up beyond the 
osseous carotid canal. Ekbom et al. interpreted this narrowing as a spasm, or 
more likely an edema of the carotid vessel wall, possibly caused by 
parasympathetically derived vasodilation. Theoretically, this edema could 
cause a distension or compression of the sympathetic plexus following the 
ICA through the petrous bone, resulting in an ipsilateral third order 
oculosympathetic dysfunction. A similar finding was observed in another 
patient who underwent interictal carotid MRI-angiography in cluster period 
(60). A third patient did not have a narrowing of the ICA on MRI-angiography 
during a spontaneous attack, but this patient did not have miosis or ptosis 
during attacks, as the former patients had. This hypothesis is now widely 
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accepted as the pathophysiological model for oculosympathetic dysfunction 
in CH, but it must be pointed out that the body of evidence is rather small.  
The theory of ICA swelling could also help to explain the forehead sweating 
during CH attacks. As mentioned, sympathetic fibers to the sweat glands of 
the medial part of the forehead follow the oculosympathetic fibers along the 
ICA. CH patients with persistent signs of oculosympathetic deficit also show 
loss of ipsilateral forehead thermoregulatory flushing and sweating between 
attacks (68). However, during attacks they often have increased flushing and 
sweating (63). This may be caused by a hypersensitivity response in 
denervated muscarinic sweat glands, responding to the parasympathetic 
efflux of the trigeminoparasympathetic reflex.  
3.5 The pupillary light reflex 
The efferent oculosympathetic fibers also constitute the efferent sympathetic 
branch of the pupillary dark response. The pupillary light reflex causing 
constriction of the pupil in response to light is parasympathetically driven 
(Figure 3). When light falls on the retina, non-image forming ganglion cells 
(intrinsically photosensitive ganglion cells) convey signals to the olivary 
pretectal nucleus in the midbrain, which projects bilaterally to 
parasympathetic neurons in the Edinger-Westphal nucleus (EWN). From 
here, preganglionic neurons are carried along the oculomotor nerves (3rd 
cranial nerve) to the ciliary ganglia in the posterior orbits. Several short 
postganglionic ciliary nerves innervate the iris sphincter muscle, causing 
constriction of the pupil.  
Redilation of the pupil seems to be a purely sympathetic response, conveyed 
by the fibers travelling through the efferent pathways described in section 
3.4. The size of the pupil reflects the net output of these opposing 
sympathetic and parasympathetic systems. The non-imaging forming 
ganglion cells of the retina also convey signals to the SCN via the 
retinohypothalamic tract (69). This connection not only allows the SCN to 
influence the pupillary dilation process, but it is also forms the basis for how 
the SCN is able to align the chronobiological rhythms of the body with the 






Figure 3: The pupillary light reflex. Light evokes the pupillary light reflex, which is 
parasympathetically driven (red lines): Non-image forming ganglion cells in the retina 
convey signals to the olivary pretectal nucleus (OPN), which projects bilaterally to the 
preganglionic parasympathetic fibers in the Edinger-Westphal nucleus (EWN). From 
here, the preganglionic fibers project to the ciliary ganglions where they synapse 
again. Postganglionic fibers reach the iris sphincter muscle and cause pupillary 
constriction. Redilation of the pupil seem to be a purely sympathetic response (green 
lines). The paraventricular nucleus (PVN) is a major sympathetic premotor nucleus 
that projects fibers to the intermediolateral column (IML) in the upper thoracic spinal 
cord. From here, second order sympathetic fibers travel to the superior cervical 
ganglion (SCG). Third-order sympathetic fibers project to the iris dilator muscle, 
causing dilation of the pupil. The locus coeruleus (LC) plays an important role in 
pupillary control (Black lines), either by contributing to the sympathetic outflow, or 
attenuating the parasympathetic outflow by inhibiting the EWN. Light also regulates 
the activity through the complex circadian system (black stippled lines) governed by 











4  Chronobiology 
 
Chronobiology is the study of biological rhythms in living organisms, and how 
they adapt to the solar and lunar cycles. These rhythms may be circadian, if 
they appear to oscillate diurnally (between 19 and 28 hours), or circannual, if 
they appear to oscillate annually or between the seasons (70). A biological 
rhythm is said to be circadian if it is endogenously generated, has a free-
running period close to 24 hours, and can be modified by environmental 
cycles with 24-hour periods. All cells and tissues of the human body manifest 
inherent rhythms that drive fundamental processes, such as metabolism and 
cell division (71). These rhythms are synchronized by the body’s master 
circadian clock, which is located in the suprachiasmatic nucleus (SCN) in the 
anterior hypothalamus.  
4.1 The suprachasmatic nucleus 
The SCN is functionally and anatomically subdivided in two cell clusters: the 
dorsomedial (shell) region, and the ventrolateral (core) region (72). The cells 
of the shell region are intrinsically rhythmical and will oscillate in close to 24-
hour loops when put in cell culture (73). These loops are caused by 
transcriptional-translational cycles of so-called clock genes. The cells of the 
core region receive external input from the retina, where the non-image 
forming ganglion cells convey light signals from the sun through the retino-
hypothalamic pathway to the SCN. Such an external time cue is called a 
zeitgeber, and the solar light-dark cycle is the most important zeitgeber 
known to man (74). The sunlight activates the core cells of the SCN, which in 
turn pass the signal on to the pineal gland via the PVN and the superior 
sympathetic ganglion. The pineal gland secretes melatonin during the night, 
and the combination of external light and melatonin synchronizes, or 
entrains, the cells in the SCN shell region to the solar light/dark cycle.  
The length of the entrained rhythm decides the period of the biological 
circadian clock, to which all biological rhythms of the body must adapt. This 
adaptation takes place through complex interactions in the dorsomedial 
hypothalamus (DMH), where the rhythmic output of the SCN and the 
subparaventricular zone is integrated with various endogenous and 
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exogenous input from the body, resulting in a periodic sleep-wake cycle, 
thermoregulation, hormone release, feeding, and more (73). Some, but not 
all blind people exhibit free-running cycles of melatonin secretion, and there 
is evidence suggesting individual differences in human sensitivity to the 
external photoperiods (74). A complete destruction of the SCN in animals will 
eliminate circadian rhythmicity of sleep, locomotion, body core temperature, 
feeding, heart rate, blood pressure, and secretion of hormones (72). 
4.2 Clock genes 
Thanks to the introduction of systems biology approaches, our knowledge of 
the clock genes has increased rapidly in the past decade (75). In early 
models, the clock mechanism was described as a simple transcription-
translation oscillator loop, where the CLOCK and BMAL1 gene proteins join 
to form a complex that initiate transcription of the PER (PER1, 2 and 3) and 
CRY (CRY1 and 2) gene families (76). The protein products of these genes 
translocate to the nucleus and inhibit further transcription from the 
CLOCK:BMAL1 complex, thereby inhibiting their own transcription. 
Degradation of the PER/CRY proteins caused by CK1δ/ε gene coded 
kinases allows the cycle to start over again, setting the intrinsic period of the 
circadian clock (the circadian period). This cycle is still regarded as the key 
transcriptional loop in clock function, but at least two additional core loops 
have been found that work alongside the CLOCK and BMAL1 genes (the so-
called D-box and RRE-loop), and it has gradually become evident that a wide 
array of gene regulators, post-transcriptional factors and multi-loop oscillators 
are involved in clock regulation. A genome-wide study screening small 
interfering RNA (siRNA) showed that more than 200 genes were involved in 
clock biology, regulating amplitude and period (77). 
4.3 Chronotype 
True endogenous rhythms should be free-running (≠ 24 h) when isolated 
from external time cues such as the light-dark cycle. Animals kept in constant 
darkness will reveal their intrinsic circadian period, and studies on humans 
have shown an average intrinsic free-running period of core temperature, 
melatonin and cortisol release of 24.18 hours (78). Together with sleep 
homeostasis and sensitivity to external light, the circadian period constitutes 
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the basis for observed diurnal preference, or chronotypes (79). Individuals 
with long circadian periods will become tired and go to sleep later in the 
evening (night owls) than individuals with relatively shorter circadian periods 
(morning larks) (80). The chronotypes represent a continuum of diurnal 
preferences, with Advanced Sleep Phase Syndrome (ASPS) and Delayed 
Sleep Phase Syndrome (DSPS) as extremes in opposite ends of the specter. 
ASPS patients get tired and go to sleep very early in the evening, while 
DSPS patients fall asleep very late at night. However, the length and quality 
of sleep is normal.  
Two mutations in clock genes have been found in familial ASPS; one in the 
PER2 gene coding for a target in the PER2 protein that is phosphorylated by 
CK1δ, and one in the CK1δ gene itself (81, 82). Interestingly, a recent study 
of two families with co-occurring ASPS and migraine showed that each family 
had its own distinct missense mutation of the CK1δ, and this mutation was 
only present in the family members who had both ASPS and migraine (83). 
Genetically engineered mice that carried one of these mutations were more 
sensitive to pain after being exposed to the migraine trigger nitroglycerine, 
and showed a lower threshold for cortical spreading depression. To my 
knowledge, this is the only study that has linked a specific headache to the 
clock itself.  
4.4 Genetic and environmental influences on chronotype 
Diurnal preference is a complex phenotype, produced by the interaction 
between the sleep and circadian systems, and modulated by the environment 
(84). Chronotype can be measured by validated questionnaires such as the 
Horne-Ostberg morningness-eveningness questionnaire (MEQ) (85), or the 
Munich Chronotype Questionnaire (86). Women seem to be more inclined to 
morning preference than men, and after adolescence there is a shift towards 
earlier chronotypes with increasing age (87). The MEQ is also influenced by 
social factors such as work schedules (88), and the tendency toward evening 
preference seems to increase with the distance from the Equator (89).  
Twin studies have shown that diurnal preference has a heritability of 44-50% 
(90-92), but systematic screens for circadian clock gene polymorphisms that 
are associated to diurnal preference in healthy populations have only been 
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moderately successful. A single nucleotide polymorphism (SNP) of the 
CLOCK gene, the T3111C (or 3092 T→C) CLOCK gene mutation has been 
associated to evening preference in two separate studies (93, 94). However, 
other studies have failed to replicate this association (95).  
The most widely replicated association between chronotype and a clock gene 
is a variable number tandem repeat (VNTR) polymorphism of the PERIOD3 
(PER3) gene, that has been associated to diurnal preference and DSPS in 
multiple studies (96-101). A VNTR occurs in DNA when a pattern of one or 
more nucleotides is repeated, and the repetitions are directly adjacent to 
each other. In the human PER3 gene, the short allele contains four tandem 
54-bp repeats, and the long allele has five such repeats. As each individual 
has two sets of alleles, this produces three possible genotypes: PER3 4/4, 
4/5 and 5/5. Most studies on PER3 VNTR polymorphism and preferred daily 
rhythm have shown an association between the long (5-) allele and morning 
preference (97). However, as with the CLOCK gene, not all studies have 
managed to reproduce the association (102). 
4.4 Circadian misalignment 
The complex interactions in the hypothalamus allow the intrinsic rhythm of 
the circadian system to be synchronized with the external environment, but 
the pacemaker cells of the SCN shell region may need several days to adjust 
to a new rhythm. A situation where the internal clock is unsynchronized with 
the external environment is called circadian mismatch or circadian 
misalignment. Jet lag and shift work disorder are common examples of 
circadian misalignment, and there is increasing evidence that such 
misalignment over time may lead to several health problems (103). Shift work 
disorder is a well-known problem affecting up to 30% of shift workers (104), 
and night shift workers have a higher risk of developing cardiovascular 
disorders, metabolic syndrome and some types of cancer compared to 
daytime workers (105).  
Circadian misalignment is a possible mechanism for the pathophysiological 
association between the biological clock and CH. That would mean that the 
internal rhythms and external zeitgebers are periodically unsynchronized, 
either because of abnormal rhythms in the biological clock itself, 
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abnormalities in the interactions between the clock and the external 
zeitgebers, or in the interactions between the clock and the hypothalamic 
input from the rest of the body. The cyclic activity of the SCN would then 
repeatedly create conditions that facilitate attacks, explaining the periodic 
occurrence of CH.  
4.5 Clock genes in cluster headache 
Only one clock gene mutation has previously been studied in CH, namely the 
T3111C CLOCK gene SNP. Three separate Italian studies, each including 
107, 101 and 54 CH patients, have assessed this polymorphism, all of which 
found no difference between CH patients and healthy controls (17, 106, 107). 
When we started our project, there had been no previous attempts to 
chronotype a population of CH patients. During the course of our work, a 
Danish study from 2014 chronotyped 275 patients using the Horne-Ostberg 
MEQ, and compared them to 145 healthy controls (29). They found no 
















5  Aims of the study 
 
5.1 Overall aim 
To study five different aspects of chronobiology in cluster headache patients: 
the periodicity of attacks, frequency of sleep disturbances, frequency of shift 
work employment, preferred daily rhythm and clock gene polymorphism. In 
addition, we aimed to study cranial autonomic function in the remission 
phase of cluster headache. 
5.2 Specific aims 
Paper 1 
To assess the periodicity of headache attacks, prevalence of chronic 
insomnia and shift work employment in an Arctic cluster headache 
population.  
Paper 2 
To study the distribution of PER3 clock gene polymorphism in cluster 
headache patients, and assess preferred daily rhythm (chronotypes) and 
frequency of sleep disturbances in the same individuals.  
Paper 3  
To study the cranial autonomic nervous system in CH remission phase, using 










6  Materials and methods 
 
6.1 Study participants and design 
6.1.1 Paper 1 
The patients were identified through a retrospective chart review at the 
Nordland Hospital Trust in Bodø and The University Hospital of North Norway 
in Tromsø. These are the two regional hospitals in the Arctic region of 
Norway, and together they serve about 450 000 inhabitants. Assuming that 
most CH patients at some point would be referred to secondary health care, 
we identified all patients diagnosed with cluster headache (ICD-10 G44.0) 
between January 1, 2000 and December 31, 2010, and validated their 
diagnosis according to the ICHD criteria through hospital charts (108). Only 
episodic CH patients were included. No reward was offered for participation.  
The study was designed as a cross-sectional, questionnaire-based survey. 
We invited all patients with a confirmed diagnosis to participate by mail, and 
asked them to fill out a comprehensive questionnaire. The questionnaire 
(appendix) was primarily developed by dr. Alstadhaug, and consisted of 92 
questions covering clinical characteristics of headache, treatment, periodicity, 
shift work occupation and sleep. Chronic insomnia was defined in 
accordance with the DSM-IV criteria (109). 
6.1.2 Paper 2 
The second paper was the result of a collaboration between our research 
group and the Norwegian Advisory Unit on Headaches in Trondheim. In 
February 2014, we included all patients registered with CH (episodic and 
chronic) in the Norwegian Advisory Unit’s biobank for genetic analysis of the 
PER3 VNTR polymorphism. The biobank contains blood samples from 
headache patients living in the middle and northern part of Norway. A 
headache specialist, who validates the diagnosis according to the ICHD 
criteria, consults all patients included in the biobank. Prior to analysis, we 
invited the patients from our first study to donate a blood sample to the 
biobank, and 48 patients did so. They were offered NOK 1000,- for the 
donation. This part of the study was designed as a case-control candidate 
gene association study, in which we compared the PER3 genotype 
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distribution in the CH population with a previously genotyped healthy 
population of 432 Norwegian students (110).  
All tested patients were subsequently invited by mail to fill out three 
questionnaires: the Horne-Ostberg MEQ, the Pittsburgh Sleep Quality index 
(PSQI) and the Shift Work Index. All three questionnaires are available in 
Norwegian translations, and the MEQ and PSQI (appendix) are also 
validated in Norwegian. We had no control group of our own, but the MEQ 
chronotypes were compared to a recently chronotyped Danish population of 
275 CH patients and 145 controls. The Danish authors kindly provided us 
with age-adjusted chronotypes. The results from the questionnaires were 
also tested for association to PER3 genotype in our CH patients.  
6.1.3 Paper 3 
In the third study, the patients who had participated in study 1, who lived in 
Nordland County, and who had agreed to participate in further studies, were 
invited to the out-patient clinic of the Nordland Hospital Trust for examination 
in remission phase. Patients with CH attacks during the last four weeks, or 
who had undergone previous ocular surgery, were excluded. We performed 
dynamic pupillometry and computer-assisted retinal vessel caliber 
measurement on both eyes on all the patients, as well as bilateral ultrasound 
measurement of the luminal diameter of the superficial temporal artery. The 
researchers that performed ultrasound and retinal vessel caliber 
measurements were blinded to which side of the head the patients had their 
headache.  
The study was designed as a case-control study. The results of pupillometry 
were compared to a group of healthy controls, which were recruited among 
hospital staff and visiting relatives of in-patients, ensuring a match in age and 
gender to the CH patients. There was no control group for the superficial 
temporal artery or the retinal vessel measurements, but the CH patients 
served as their own controls, as headache-affected side was compared to 
asymptomatic side both when examined by pupillometry, ultrasound and 
retinal vessel measurements. If the patients had side shift of their headache, 
we defined the predominant side as symptomatic.  
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6.2 The DSM IV criteria for chronic insomnia 
The diagnosis of chronic insomnia requires the presence of both criteria A 
and B (109): 
A. The predominant complaint is difficulties initiating or maintaining sleep, or 
nonrestorative sleep, at least three nights a week, for at least one month. 
B. The sleep disturbance (or associated daytime fatigue) causes significant 
distress or impairment in social, occupational, or other important areas of 
functioning. 
6.3 DNA isolation and PER3 genotyping 
DNA was extracted and purified from blood specimens from the Headache 
biobank, and polymerase chain reaction (PCR) amplification of the PER3 
polymorphism was performed according to previously validated methods 
(110, 111). Table 1 shows forward and reverse primer, as reported by 
Ebisawa et al. (2001). 
   
Direction Sequences     
Forward: 5' CAAAATTTTATGACACTACCAGAATGGCTGAC 3' 
Reverse: 5' AACCTTGTACTTCCACATCAGTGCCTGG 3' 
 
Table 1. Primer sequences. 
 
6.4 The Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ) 
The MEQ is one of the most widely used and best validated tools for 
measuring diurnal preference (85). It consists of 19 multiple-choice items, 
producing a score ranging from 16 to 86, with high scores indicating morning 
preference and low scores indicating evening preference. The initial 
chronotype cut-off points were validated for a population of young students, 
and as chronotype is strongly influenced by age and social factors, validated 
cut-off points for a middle-aged, non-shift working population have later been 
made by Taillard et al. (112). We used these cut-offs for our study, defining 
evening types: MEQ scores 16-52, neither types: MEQ scores 53-64, and 
morning types: MEQ scores 65-86. 
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6.5 The Pittsburgh Sleep Quality Index (PSQI): 
The PSQI is a validated, retrospective measure of subjective sleep quality 
and sleep disturbances during the past month (113). It consists of 19 items 
grouped into seven equally weighted component scores, with higher scores 
indicating poorer sleep quality.  The maximum score is 21, and a score 
above five indicates a poor sleeper.  
6.6 The Standard Shiftwork Index (SWI):  
The SWI is a standardized battery of questions developed to study the 
psychological and physiological impact of shift work (114). We used it mainly 
to identify shift workers, as the small number of participants made detailed 
studies on adaptation to different shifts less reliable.  
6.7 Dynamic pupillometry of the light reflex 
We used a handheld NeurOptics PLR-200TM pupillometer for recordings. This 
device samples data at 32 frames per second, and has a documented high 
accuracy with no more than maximum 0.3 mm difference from infrared 
photography measurement (115). We equipped a specialized room for the 
procedure, and made a standardized procedure for measurement by which 
all participants were examined. The subjects were adapted to darkness (at 1 
lux ambient illumination) for 2 minutes before every measurement, recording 
one pupil at a time, starting with the left side. Sitting in a chair, they were 
asked to focus on a black spot on the wall 5 meters away. The device first 
recorded the maximum diameter of the pupil (Max), before a light flashed 
with180 micro Watts and 802 milliseconds duration. The following values 
were obtained: Minimum diameter of the pupil (Min), constriction in percent 
(Con=Max-Min/Max), onset of constriction in seconds (Lat), average and 
maximum constriction velocity in millimeter per second (ACV and MCV), 
average dilation velocity (ADV), and the total time in seconds to recover 75% 
of pupil resting size after peak constriction (T75).  
The pupillometric measures reflecting sympathetic function include: Max, 
ADV and T75. As the T75 increases linearly with the amplitude of the light 
reflex (116), calculations were made using the T75/A ratio, where A is the 
amplitude of the reflex in millimeters (Max-Min).  
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Measures reflecting parasympathetic function include: Con, MCV and 
ACV.  
6.8 Measurement of the luminal diameter of the superficial temporal artery 
For ultrasound measurement of the superficial temporal artery, we used a 
high resolution Vivid Cardiovascular Ultrasound Systems (Vivid 7, GE 
Medical Systems, Little Chalfont, UK). The participants were placed in a 
supine position, and the main trunk of the superficial temporal artery was 
located by palpation just in front of the ear in the meato-orbittal line. A wide 
band (4.7 13 MHz) linear 1.25D matrix array transducer was oriented parallel 
to the artery and a longitudinal section of the main trunk visualized. From a 
0.5 cm segment, three diameter measures were obtained (from intima to 
intima), and the average diameter was used as the reference diameter of the 
artery. The measurement was then repeated on the contralateral side.  
6.9 Measurement of retinal arteriolar and venular diameter  
Both pupils were dilated with one drop of Tropicamide 0.5% (Chauvin 
Pharmaceuticals Ltd. Kingston upon Thames, Surrey, England), and an 
FF450 plus IR Fundus Camera (Carl Zeiss Meditec, Jena, Germany) 
captured optic nerve centered retinal photos of both eyes. Retinal vascular 
diameters were measured computer-assisted with IVAN, the updated version 
of Retinal Analysis software (University of Wisconsin, Madison, USA) (117). 
All vessels with a diameter of more than 35-40 µm, coursing through the 
retina within one-half to one disc diameter from the optic disc margin, were 
measured. The six largest of each vessel type were summarized as the 
central retinal artery equivalent (CRAE) and the central retinal vein equivalent 
(CRVE) (118). The protocol for grader-interaction on the automated 
measures was in accordance with previously validated protocols (117) with 
minor modifications according to the Retinal Vascular Imaging Centre 
(RetVIC) (Centre for Eye Research Australia, University of Melbourne, 
Australia).  
6.10 Statistical analysis 
Data were analyzed using the SPSS software package for Windows version 
18.0, 20 and 21 (SPPS Inc., Chicago, IL, USA). All p values were two-tailed, 
and a significance level of 0.05 was used for all analysis. In paper 1, chi-
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square tests were used for comparing frequencies, and independent t-tests 
for comparing means. In paper 2, a chi-square test was used to compare 
frequencies of genotypes and chronotypes, whereas the association between 
genotype and MEQ or PSQI scores was tested in a multiple linear regression 
model, adjusting for age, gender and shift work.  
In paper 3, the superficial temporal artery and retinal vessel caliber 
measurements were analyzed with a paired samples t-test, comparing the 
headache affected side with the asymptomatic side in each patient. 
Measurements of the pupillary light reflex by pupillometry were analyzed both 
in a repeated measures analysis of variance (ANOVA) and in an independent 
samples t-test. In the repeated measures ANOVA, side was set as the within-
subjects factor (affected vs. not affected side in patients, right vs. left side in 
controls), and patients vs. controls was set as the between-subjects factor. In 
the independent t-tests, both affected and not affected side in CH patients 















7  Summary of results 
 
7.1 Paper 1 
196 patients were identified. Seventy patients were included in the analysis, 
58 men and 12 women (Figure 4). Mean age was 49.3 years (SD ± 13.8). 
Mean age of CH onset was 32.5 years (SD ± 13.4), and mean time to 
diagnosis was 5.8 years (SD ± 6.8). The majority of patients (54%) had ≥ 
three CH attacks per day, and one third of patients (36%) had ≥ two cluster 
bouts per year. For demographics and clinical characteristics, please see 
paper 1. 
Of the final 70 participants, 31 (44%) reported that their CH bouts came at 
regular intervals of the year. February was the most frequent month of onset, 
followed by October and November. Twenty-six responders (37%) said that 
their bouts came at specific seasons, mostly spring (20%) and autumn (13%) 
(Figure 5). CH attacks came at fixed times during the day in 41 responders 
(58.5%), with the most frequently cited interval between 12 and 4 a.m. 
(Figure 6). Fifty-six responders (80%) often or always had CH attacks during 
sleep. Sleep was reported as the most frequent trigger of attacks (48.5%), 
followed by bright light (41.5%), lying flat (38.5%), alcohol (31.5%) and lack 
of sleep (18.5%).  
Twenty-eight of the seventy participants (40%) met the DSM IV criteria for 
chronic insomnia. The insomniacs reported shorter time from onset of 
symptoms until diagnosis (3.9 vs. 7.1 years, p=0.050) and significantly longer 
lasting CH bouts (8.7 vs. 5.1 weeks, p=0.022) than the non-insomniacs. 
About one third of the insomnia-patients (35.7%) attributed their insomnia to 
CH. There was no difference in gender, age, self-reported chronotype (night 
owls vs. morning larks), periodicity of headache, comorbidity or the frequency 
of receiving social benefits between patients with and without insomnia, but 
there were significantly more shift workers among the insomniacs (60.5% vs. 
39%, p=0.034). Sleep, or the lack of it, was not a more frequent trigger of 














Figure 5: Seasonal distribution of CH bouts in 70 Arctic CH patients. 
 
Figure 6: Daily distribution of CH attacks in 70 Arctic CH patients. 
 
Of the 45 responders currently working, 22 (49%) were shift workers, and of 
the total study population, 33 (47%) reported current or previous shift work. 
As noted, there was an association between shift work and insomnia.  
Previous and current shift workers were significantly more likely to see lack of 
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7.2 Paper 2 
Genetic analysis of the PER3 VNTR polymorphism was performed in 149 CH 
patients (109 men and 40 women, mean age 54.1 years, SD±14.0). The 
genotype distribution was as follows: PER3 4/4: 45%, PER3 4/5: 43.5%, and 
PER3 5/5: 11.5%. Compared to 432 healthy controls, there was no difference 
in PER3 VNTR polymorphism (p=0.992).  
Seventy-four CH patients completed all three questionnaires (the MEQ, PSQI 
and SWI) and were included in subgroup analysis. There were 54 men and 
20 women, with a mean age of 52.3 years (SD ± 13.4). The mean MEQ-
score was 51.4 (SD ± 10.5), and based on individual values we found the 
following chronotype distribution: 38 (51%) evening type, 27 (37%) 
intermediate type, and nine (12%) morning type. There was no difference in 
chronotype distribution when compared to a previously published Danish CH 
population or their healthy controls (p=0.595) (29).   
The mean PSQI was 8.4 (SD ± 4.6), and 44 CH patients (60%) were defined 
as bad sleepers (PSQI > 5). Of the 49 patients currently employed, 25 (51%) 
were currently shift workers, and another nine (18%) had previously worked 
shift. Of the total group of 76 responders, 40 (52%) were current or previous 
shift workers. 
There was no association between shift work employment and PSQI score 
(p=0.343). We found no association between PER3 VNTR polymorphism and 
chronotype (p=0.352). Multiple linear regression adjusting for age, gender 
and shift work showed no association between PER3 genotype and MEQ or 
PSQI scores.  
7.3 Paper 3 
Thirty patients were included in the analysis: 27 men and three women with a 
mean age of 50.2 years (SD ± 13.6). Thirty healthy controls were included for 
dynamic pupillometry (27 men and three women, mean age 50.3 years, SD ± 
13.6).  
When comparing the headache-affected side to the asymptomatic side in CH 
patients, pupillometry showed a significantly reduced average constriction 
velocity of the pupil on the headache-affected side (p=0.007). When 
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comparing CH patients to healthy controls, we found a statistically significant 
reduction in all measures of parasympathetic function on both eyes (average 
constriction velocity, mean constriction velocity, constriction in percent and 
constriction latency). The differences were more pronounced on the 
headache-affected side. 
We found no differences in the superficial temporal artery diameters between 
the headache-affected and the asymptomatic side (p=0.525). 
The mean central retinal vein equivalent (CRVE) on the headache-affected 
side was significantly smaller than on the asymptomatic side (221.10 µm vs. 
226,60 µm, p=0.043). The mean central retinal artery equivalent (CRAE) was 
also slightly smaller on the headache-affected side, but this was not 

















8  Methodological considerations 
 
8.1 External validity- sampling bias 
CH is a relatively rare disease, and research on rare diseases is often 
hampered by small sample sizes. This poses a threat to the external validity 
of the studies, as the results from the study population may not be 
representative to all CH patients. External validity refers to what extent the 
results of a study can be generalized and valid to people beyond the study 
population, which in our case would mean beyond CH patients living in the 
North of Norway. 
In the first study, we presumed that most CH patients would be referred to 
secondary care at some point, and that our chosen method of recruitment 
would identify the vast majority of patients in our region. We identified 196 
patients, which would give a prevalence of 0.04% in North Norway. This is 
lower than expected. We have no reason to believe that the prevalence of 
CH is lower in this region than in other geographical areas, although it is 
possible. Five of the 88 responders even appeared to have been wrongly 
diagnosed, indicating a potential misclassification bias. Nevertheless, we 
probably missed a proportion of patients, and there may be a sampling bias 
in our material. A sampling bias is by most researchers classified as a 
subtype of selection bias, in which a sample is collected in such a way that 
some members of the intended population are less likely to be included than 
others. A distinction between sampling and selection bias is that while 
selection bias is usually regarded as a problem for the internal validity, the 
sampling bias may affect the external validity and undermine the 
generalizability of the study results.  
The patients identified in paper 1 had all been in contact with secondary 
health care during the 11 years defined in the study. This could either mean 
that they are more affected by their headache than the ones we potentially 
missed, and forced to seek help for it, or that they are less affected by their 
headache, and therefore more able to take action in their suffering. 
Alternatively, patients diagnosed before 2000 did not make contact because 
of previous experiences with the healthcare system, either good or bad.  
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8.2 Internal validity – selection bias 
The internal validity of a study refers to how valid the results are for the 
actual study population. The internal validity is usually not affected by 
random errors, but will be threatened by systematic errors such as selection 
bias, information bias and confounding. In addition, the internal validity may 
be reduced by the use of incorrect statistical methods and effect sizes. The 
risk of a selection bias in our first study was reinforced by the low response 
rate of only 49% (88/178). The response rate in study 2 was also low at 53% 
(80/149). Studies show that response rates in surveys based on postal 
questionnaires are generally low, sometimes as low as 20% (119). 
Nevertheless, we may have a volunteer bias in our population. Usually, the 
sickest patients are less likely to participate in studies. This is called the 
healthy user bias.  
When comparing the responders to the non-responders in paper 1, we found 
no difference in age, gender or shift work occupation between the groups. In 
addition, the general demographic and clinical findings in our studies are very 
much in accordance with previous published studies on other CH populations 
(3, 6-8, 29). We therefore believe that, in spite of low response rates, the 
participants included in the studies are representable to the CH population in 
the region. 
8.2 Internal validity - recall bias 
In addition to a selection bias, our data may also be affected by a recall bias. 
This is a classic form of information bias, where the participants in 
retrospective studies may recall events differently in different groups. Their 
recollection may be influenced by the purpose of the study, or by the nature 
of the questions asked. Our questionnaire asked about periodicity of 
headache and sleep disturbances in retrospect, and simply by asking these 
questions we risk to overestimate the frequency of both. A prospective 
design would have been the best way to assess both periodicity and sleep 
disturbances. Unfortunately, prospective designs are quite difficult to achieve 




8.3 Statistical power in genetic studies 
Low statistical power is an important threat to the statistical validity of a 
study, and this is the greatest limitation to the genetic association analysis in 
paper 2. Power calculations in genetic association studies rely heavily on the 
effect size that the candidate gene exerts on the disease or trait studied. In 
this case, the effect size is unknown, and calculating power must therefore 
be based on presumptions. It is generally accepted that common complex 
diseases are unlikely to be caused by a single locus of large effect, and that 
genotypic relative risks are likely to be in the range of 1-1.5 (120). CH is not a 
common disease, but it is most probably of complex genetic origin, and we 
should not presume the effect of a single allele to be too large. If we use the 
Purcell Genetic Power Calculator (121) and assume an additive model, a CH 
prevalence of 0.2%, a frequency of the PER3 5-allele of 0.33, and a relative 
risk of 1.5 for the 5/5 genotype to have CH compared to the 4/4 genotype, we 
would find a statistical power of 46% in our study. Raising the presumed 
relative risk of the 5/5 genotype to 2.0 increases the power to 89%. As the 
former seems a more realistic presumption, our study is most probably 
underpowered. This means that we are at risk of not finding an effect in our 
study, when in reality there is an effect (type II error).  
Studies with low statistical power are regarded as an increasing problem in 
neuroscience (122). The low power not only reduces the chance of detecting 
a true effect, but also reduces the likelihood that a statistically significant 
result reflects a true effect. In other words, low power produces low positive 
predictive values. In addition, when a true association is detected, the 
magnitude of the effect is often exaggerated, making the risk of not 
confirming the association in replication studies large. This is called the 
“winners curse”, and is likely to occur in situations where a threshold, such as 
statistical significance, is used to define a positive finding. A meta-analysis of 
neuroscience articles published in 2011 indicated a median statistical power 
of 21% (122). To compensate for the general lack of power in studies of 
genetics, it is recommended to set the level of significance to 0.01, instead of 
the usual 0.05. This will reduce the risk of making a type I error, but it also 
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increases the risk of a type II error (123). We used a significance level of 0.05 
in our paper, but the results were still negative.  
The limited access to patients makes large genetic studies on CH difficult to 
conduct. However, genetic studies are important to develop a better 
understanding of the pathophysiology even in rare headache disorders, and if 
strict rules of statistical power were to be followed, very little research would 
be done on these conditions. We therefore believe that despite its small 



















9  Ethical aspects 
The research protocols for each of the three projects were reviewed and 
approved by the Regional Ethics Committee of North Norway before 
inclusion of patients. The patient’s privacy, physical and mental integrity, 
personality as well as confidentiality was respected and protected through all 
three studies, in accordance with the World Medical Association Declaration 
of Helsinki (124). Participation in all projects required a written, informed 
consent. The subjects could at any point withdraw the consent.  
The use of biobanks in medical research requires special attention to ethical 
considerations. In Norway, biobanks used for research are regulated by the 
Health Research Act of 2008 (www.lovdata.no/dokumen/NL/lov/2008-06-20-
44 ). The Health Research Act defines who may initiate and terminate a 
biobank, how the specimens should be stored and treated, who should have 
access to the biobank, and how to transfer specimens from one country to 
another. The ethical debate concerning the use of biobanks have increased 
proportionally with the number of biobanks the last years (125). Three topics 
in particular have been frequently discussed (126): 1) What is an adequate 
informed consent in a biobank setting? Should the participant give a general 
consent that includes all possible projects that might occur in an 
unpredictable future, or should he be asked for consent every time a new 
project is initiated? 2) How do you secure confidentiality for all participants, 
data security and facilitate research at the same time? 3) How do you handle 
research results or incidental findings that might be of interest to the 
participants or their genetic relatives? 
In our second study, we used blood samples from an existing biobank, in 
which the majority of the donators had given their consent and samples 
ignorant of the fact that it would be used for a study on clock gene 
polymorphism in the future. They were only made aware of our study when 
they received a follow-up invitation to complete the three questionnaires after 
the blood samples were tested. They could decline participation in the 
questionnaire-based part of the project, but they could not refuse the use of 
their blood to genetic testing. When being asked to contribute to a biobank 
the participant should be informed that this might happen, but the rapid 
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increase of biotechnological research has made it virtually impossible to 
inform the patients of every thinkable use of their donations, putting the 
concept of informed consent to the test. The informed consent has been the 
foundation of research ethics since the Nürenberg process following World 
War II. In the biotechnological area, this ideal is often put up against the duty 
of the researcher to ensure that the participants’ donations come to the best 
possible use, giving as much new and valid knowledge as possible.  
Genetic information is special in the sense that it may be of importance not 
only to the donator himself, but also to his biological relatives. We did not 
offer our patients to be informed of the results from the genetic analysis. The 
PER3 VNTR polymorphism is not linked to any disease or pathological 
processes that we know of today and the information would be of little clinical 
importance to the patient. There is consensus that individual feedback on 
results only should be done in cases where incidental findings could have 
serious consequences for the donator’s life, health or reproductive abilities, 
and where the condition is potentially curable or treatable (127). Otherwise, 
return of results could contribute to “the therapeutic misconception”; a 
phenomenon in which the research participator believes that he will benefit 
personally from participation, even though it is explicitly explained in the 
information given that the results only will be of benefit to future patients, or 













10.1 Chronobiology in cluster headache 
10.1.1 External light cues 
The periodicity of headache attacks and bouts in our Norwegian Arctic 
population is very similar to the periodicity reported in previously published 
CH populations from other parts of the world (3, 7, 8, 29). The patients in our 
study live north of the Arctic Circle, a region with extreme differences in 
daylight throughout the year, ranging from 24 hours daylight in the middle of 
the summer, to 24 hours darkness in the middle of the winter. As external 
light is the most prominent zeitgeber to the human biological clock, this 
makes it a particularly interesting location for studies on chronobiology.  
If the theory of circadian misalignment in CH is true, and changes in external 
daylight is the key external zeitgeber that causes this misalignment, one 
might expect more CH patients reporting on periodicity in the Arctic, or even 
a higher incidence of the disease. This is not the case. It is of course possible 
that the people living in the region through generations have been selected, 
or adapted, to the special light conditions. However, in our modern world the 
effect of external light cues is probably reduced by indoor illumination and the 
activities of social life. Studies of seasonal variation in human birthrates show 
that the seasonal trends seen in many populations weakened markedly after 
the industrialization in the 1930s, when people started working indoors (128). 
Likewise, chronotypes correlate with how much time a person spend 
outdoors, progressively advancing by more than an hour when people spend 
up to two hours per day in natural daylight (129). Beyond two hours, the 
chronotype changes very little. In consequence, the net effect of the sun may 
end up the same in our Arctic region as in the rest of the industrialized world, 
because we all lead similar lives.  
Nevertheless, humans living indoors in urban cities still show weak signs of 
seasonal variation in melatonin secretion and reproduction rates (130, 131), 
implying that the external light affects them. Other external factors such as air 
temperature and humidity also varies across the seasons, and air 
temperature is probably the second most important external zeitgeber 
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affecting the biological clock (128). A recent study from Taiwan showed that 
changes in temperature following a warm or cold period were associated to 
the occurrence of CH bouts (132). Most of our patients reported cluster bouts 
in the spring or autumn, which could support both a theory of rapid day-to-
day changes in daylight hours, or changes in temperature, as the 
predisposing event. Of note, bright light was the second most frequent trigger 
of CH attacks in our cohort. Researchers on chronobiology have suggested 
that the sensitivity to light may differ between individuals (74), which may 
explain why some CH patients show a clear periodic occurrence and others 
not. It may be that predisposed individuals are unable to adapt completely to 
the external time cues if they continue to change drastically over a longer 
period, as they do in the spring and autumn. Hence, we cannot rule out 
circadian or seasonal misalignment with external light or other zeitgebers as 
a predisposing factor for facilitating CH.  
10.1.2.Shift work 
Shift work occupation is another common cause of circadian misalignment. 
We are the first to assess the frequency of shift work occupation in CH 
patients. Manzoni et al. found that CH patients often had occupations with a 
high degree of responsibility, such as manager, municipal policeman or 
businessman, but he did not register shift work as such (133). He also found 
an increasing incidence of CH among women from 1955 to 1995, and 
associated this to an increase of female smokers and a higher employment 
rate (134). Sjöstrand et al. found that significantly more CH patients worked 
full time compared to their non-affected relatives (135).  
Of the responders currently working, we found 49% shift workers in the first 
study, and 51% in the second study. Of all the patients included, about 50% 
reported shift work in both studies. It should be pointed out that some of the 
patients participated in both studies. In 2012, 33% of the adult Norwegian 
work force worked outside regular office hours (Monday – Friday 08.00-
18.00), and 24% worked regularly rotating shifts including nights and 
weekends (136). Unfortunately, none of our studies were able to pinpoint 
which category the CH patients belonged to, but one could argue that the 
phrase “shift work” in Norwegian usually means rotating shifts. When 
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comparing different gender and age groups to the general population, the 
number of shift workers among the CH patients still seems high (Paper 1). It 
is well known that shift work over time may lead to health problems and sleep 
disturbances (104). In accordance with this, the shift workers in paper 1 
reported significantly more sleep disturbances than the daytime workers did. 
However, in paper 2 there was no association between shift work 
employment and PSQI score.  
The shift workers reported in paper 1 were more inclined to see lack of sleep 
as a trigger for attacks than the daytime workers. However, the patients who 
suffered from insomnia did not see lack of sleep as a trigger for attacks more 
often than those not suffering from insomnia. This could imply that it is not 
merely being awake at night that triggers attacks, but also being physically 
and mentally active, working at hours when the body is programmed to rest 
and sleep. It would be interesting to know when the shift workers experience 
their attacks – do they occur immediately after or during shifts, or does shift 
work cause sleep disturbances that further initiate attacks? If shift work is a 
trigger or risk factor for developing the disease, this could explain the high 
prevalence of shift workers in the CH population. However, it could also be 
the other way around; the CH patients choose to work shift because it suits 
their inherent rhythm better. The high frequency of shift workers may be 
specific to our population and should be confirmed in other CH populations.   
10.1.3 Sleep disturbances 
We found a high frequency of sleep disturbances among the CH patients 
both in study 1 and 2. In the first study, 40% of responders met the DSM IV 
criteria of chronic insomnia. There was a significant association to shift work 
employment, which made shift work a possible confounding factor. However, 
there was no association between shift work and PSQI score in the second 
study. The mean PSQI score was high (mean 8.4 ± 4.6), and 60% of patients 
was defined as bad sleepers with a PSQI score above five. This seems like a 
high score even when compared with other headache populations. For 
example, in a study from 2009, the mean PSQI was 5.9 ± 3.0 in migraine 
patients suffering from ≥ eight migraine days per month (137).  
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The prevalence of sleep disturbances is probably a bit higher in the Arctic 
regions because of the special light conditions. The prevalence of insomnia 
in the adult general population of Norway is estimated to 11.7% (138), and in 
mid-Norway 13.5% (139). In the high North, 17.4% of the adult population 
report sleep disturbances linked to a specific season, most often during the 
polar night (70%) (140). In a study of female migraine patients in North 
Norway, just under 30% suffered from chronic insomnia according to the 
DSM IV criteria (141). In conclusion, the prevalence of sleep disturbances is 
CH is high, even when compared to other headache populations in the same 
region. One third of the patients suffering from insomnia in paper 1 attributed 
their sleep disturbances to cluster headache, confirming previous studies 
suggesting that the majority of CH patients do not have sleep problems 
simply because they are woken up by nocturnal headache attacks (29).  
Recently, a large controlled study has assessed sleep quality in CH for the 
first time using polysomnography (142). In this study, the authors found no 
temporal relationship between CH attacks and specific sleep stages, but CH 
patients in bout had a reduced percentage of REM sleep, longer REM 
latency and fewer arousals compared to the healthy controls. They could not 
confirm a higher frequency of sleep disordered breathing in the CH group as 
previous studies have implied, but pointed out that certain risk factors such 
as smoking and male gender are frequent in the CH population, which may 
aggravate an existing disorder. 
Nocturnal sleep was the single most important trigger of attacks in our study, 
regardless of the presence of sleep disturbances. This seems to add to the 
proposed theory that cluster attacks are elicited in a state of hypoarousability 
(27). The balance between sympathetic and parasympathetic dominance in 
healthy individuals differ between REM and NREM sleep stages (73). In 
addition, there is a transient decrease in sympathetic tone during the night, 
which is reflected in a period of reduced blood pressure and heart rate (143). 
This “dipping” is found even in individuals kept awake and in supine position, 
and seem to be a result of circadian oscillations in cardiovascular tone. As 
we have seen, most CH attacks occur late at night or during the early 
morning hours, seemingly coinciding with the dip in sympathetic tone. 
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The circadian period and sleep homeostasis are more interconnected at the 
molecular level than previously thought (144). The traditional model of sleep 
regulation depicts sleep timing as the result of two independent processes; 
the circadian oscillation of the SCN, and the sleep homeostasis that tracks 
sleep need. Sleep need and the ability to initiate sleep build up during 
wakefulness and decrease during sleep. Slow oscillations of the EEG in 
NREM sleep, quantified as delta power, vary as a function of time awake and 
asleep, and are used as a reliable measure of sleep need. EEG studies of 
PER3 5/5 and 4/4 homozygote individuals show that the PER3 5/5 genotypes 
have higher delta power during sleep, and higher theta and alpha activity 
during wakefulness, compared to PER3 4/4 genotypes (79). This reflects a 
greater buildup of sleep need in the 5/5 homozygotes. However, the 
circadian rhythms of melatonin, cortisol and peripheral PER3 mRNA 
expression are not affected. This shows that clock genes may affect sleep 
homeostasis directly, without disturbing the circadian period. In the same 
manner, PER3 genotype has been shown to affect the sympathovagal 
balance in cardiac control during sleep (145). This direct relationship 
between the clock genes, sleep and autonomic tone is particularly interesting 
in view of CH, where sleep disturbances and autonomic dysfunction are 
common features.  
10.1.4 The clock 
The PER3 gene tested in paper 2 is the second core clock gene to be 
sequenced in a CH population, after the T3111C CLOCK gene 
polymorphism. Neither of the genes showed any association between gene 
polymorphism and CH. However, when taking into account the complexity of 
the biological clock and its interactions, the lack of association between two 
single gene loci and a trait does not disprove an actual link. In fact, a single 
candidate gene association study seems to be a too simplistic approach for 
assessing genetic association in this setting, although the gene is selected 
for plausible reasons. In addition, lack of association could be due to small 
sample sizes. Larger studies, including both more patients and multiple 
genes, should be sought. 
54 
 
Chronotype may be regarded as an observable expression of clock period 
and function (phenotype). Although 51% evening types in our CH population 
seems high, we found no certain difference in chronotype distribution 
between our patients and the Danish CH patients, nor their healthy controls. 
As mentioned, the tendency toward evening type seems to increase with the 
distance from the Equator, which may explain why there are more evening 
types in our population (99). An age-adjusted control group at the same 
latitude could would have increased the validity of our findings. However, the 
results are in accordance with the Danish study who found no difference in 
chronotype between CH patients and healthy controls (29), and as discussed 
in section 10.1.1, social and demographic factors may mask a true difference 
in circadian period. 
In conclusion, we have not found definite evidence of clock dysfunction in our 
CH population, but this does not mean that the clock is not involved in CH 
pathophysiology. The periodicity of attacks and high frequency of shift work 
and sleep disturbances still point at a connection. The question is where to 
look further: 1) The problem may lie within the SCN itself, where a 
disturbance in clock function causes irregular or contradictory signals, or 
failure to synchronize with external zeitgebers. 2) The problem may be 
located in the DMH, which has the difficult task of orchestrating the rhythmic 
expression of the SCN to the various influx from the rest of the body. 3) The 
problem may be abnormal processing in other hypothalamic nuclei involved 
in pain and/or autonomic function. 
10.2 The cranial autonomic nervous system in cluster headache 
In paper 3, we report a statistically significant attenuation of the pupillary light 
reflex in CH patients on both eyes compared with healthy controls. All the 
pupillometric measures of parasympathetic activity were reduced, and the 
reduction was significantly more pronounced on the headache-affected side 
when compared to the asymptomatic side. In addition, we found significantly 




10.2.1 Retinal vessels in cluster headache 
The vessels of the retina are autoregulated, and not under direct control by 
the autonomous nervous system, as are the choroidal vessels and the 
ophthalmic arteries (146). The central retinal artery is richly innervated by 
both sympathetic and parasympathetic fibers up to the lamina cribrosa (147), 
but no autonomous nerve fibers have been documented inside the retina. 
The overall goal for the autoregulation is to secure optimal blood flow in to 
the retinal vascular bed under different conditions of perfusion pressure and 
metabolic needs. This is achieved by arteriolar caliber changes and capillary 
recruitment, involving myogenic responses, metabolic signals and endothelial 
function. In addition, both α- and β-adrenergic, muscarinic and angiotensine-
II receptors have been located in retinal vessels (148-150).  
In a study of ophthalmic artery blood flow velocity in CH patients during 
Valsalva maneuver, the researchers found an ipsilateral tonic vasodilatory 
state during cluster bout and a state of increased peripheral vascular 
reactivity in remission phase (151). According to the authors, the findings 
reflected a low resistance vascular bed on the headache side in remission 
phase, with enhanced vasodilatory responses to stimuli. Another study found 
reduced intraocular pressure (IOP) and ocular pulsatile flow in CH remission 
phase compared to controls (152), consistent with reduced ocular blood flow, 
possibly caused by increased pre-ocular vascular resistance, either in the 
ophthalmic or internal carotid arteries. In general, the mean ocular perfusion 
pressure equals the mean blood pressure of the ophthalmic artery minus the 
pressure of the veins leaving the eye, and the pressure of the veins is very 
close to the IOP. Hence, small retinal veins may reflect a reduced IOP.  
Studies on retinal vessels in CH are scarce, but a recent study of retinal 
nerve fiber layer (RNFL) thickness measured by optical coherence 
tomography (OCT) found a significant thinning of the RNFL in the temporal 
areas on both eyes of CH patients compared to healthy controls (152, 153). 
In the nasal area, they found the RNFL to be thicker. Reduced RNFL have 
also been reported in migraine patients (154). As the thickness of the RNFL 
measured by OCT seems to correlate with the main branches of the retinal 
arterioles and venules (155), the authors explain their findings as a result of 
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inter-attack retinal vessel vasodilation on the nasal side, and possibly 
oxygen-induced vasoconstriction on the temporal side. They do not theorize 
on what could cause the alleged vasodilation in the nasal areas, but point out 
that the vessels have more branches in this area.  
None of our patients used oxygen, and we do not have information on the 
vessel caliber in the different regions of the retina in our study. Both retinal 
arterioles and venules were smaller on the symptomatic side, although not 
statistically significant for the arterioles. As the retinal vessels are 
autoregulated, the findings of our study are most compatible with a reduced 
total blood flow to the eye on the headache side, relative to the asymptomatic 
side. What could cause such a flow reduction is unclear. Repeated 
parasympathetic storms and vasodilation during attacks may produce local 
vasoactive substances or environmental changes that continue to affect 
retinal vessels even in the remission phase. Alternatively, the reduced blood 
flow may represent an altered pre-ocular autonomic tone, either a relative 
increase in upstream sympathetically derived vasoconstriction, or a relative 
decrease in upstream parasympathetically derived vasodilation. As the 
pupillometry showed no signs of oculosympathetic dysfunction, the former 
seems less likely. We therefore suggest that our findings imply a reduced 
parasympathetic pre-ocular vascular tone on the headache-affected side 
relative to the asymptomatic side in CH patients. 
10.2.2 The pupillary light reflex in cluster headache 
Attenuated pupillary light reflexes compared to healthy controls have also 
been documented in migraine patients, measured with pupillometry within 48 
hours of spontaneous migraine attacks (156). However, when examined 
again one week later, there were no differences in pupillary light reflexes. 
Hence, it is possible that attenuated pupillary light reflexes are a general and 
transient phenomenon following episodic headache. We know that the time 
lapse from last attack was at least four weeks in our patients, so it would 
seem like a more permanent finding in our case. Our results seem 
contradictory to previous studies, as most of them found evidence of 
oculosympathetic dysfunction. However, most of these studies were carried 
out in the pain-free interval of the cluster bout, which most probably is a 
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different autonomic state than the remission phase. In addition, most studies 
used pharmacological tests to measure pupillary responses, which may be a 
more potent trigger of sympathetic responses than light. Drummond et al. 
recorded pupillary responses to light in 30 CH patients immediately before, 
during, and within one hour after attack, and found increased pupillary 
constriction velocity and decreased dilation velocity consistent with increased 
parasympathetic and decreased sympathetic activity (157). The increased 
parasympathetic activity was less pronounced one hour after the attack. Our 
findings may represent a chronic downregulation of parasympathetic output 
in remission phase, possibly to avoid further attacks.  
10.2.3 The locus coeruleus 
We know that the locus coeruleus (LC) plays an important role in the 
pupillary control, both by inhibiting parasympathetic and stimulating 
sympathetic output to the eye (69). The LC attenuates the pupillary light 
response by inhibiting the EWN, and it enhances oculosympathetic outflow 
by excitatory projections to preganglionic sympathetic neurons (Figure 3). 
Noxious stimuli dilate the pupils without affecting the light reflex (reflex 
dilation), most probably by activation of the LC. However, anxiety and 
conditioned fear, in which a neutral stimulus produces anticipation of a 
noxious stimulus, cause both reflex dilation and attenuation of the light reflex. 
This suggests activation of both sympathetic and parasympathetic premotor 
neurons by the LC.  
The LC is the main noradrenergic nucleus of the brain. It is connected to a 
number of regions in the hypothalamus and forebrain, and is involved in a 
number of vital functions such as wakefulness, responses to stress, 
regulation of emotions and modulation of pain. The LC densely innervates 
the neurons of the trigeminal sensory nucleus (Figure 2), and activation of 
the LC inhibits the neurons of the trigeminal nucleus involved in pain 
perception (158). It is possible that the LC may be involved in terminating the 
pain in headache attacks. In a recent neuroimaging study, migraine patients 
were shown to have increased hypothalamic functional connectivity with a 
number of brain regions involved in autonomic functions, including the LC 
(159). What is more, the LC also inhibits the parasympathetic outflow of the 
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SSN, which is responsible for the CH attack-related cranial vasodilation 
(158). In other words, activation of LC may explain both our main findings 
reported in paper 3: a reduced pupillary light reflex caused by inhibition of the 
EWN, and reduced vasodilation of ipsilateral pre-ocular arteries, caused by 
inhibition of the rostral, ventrolateral region of the SSN.  
10.2.4 The paraventricular nucleus 
The PVN is another important hypothalamic nucleus involved in pupillary 
control. When light hits the retina, the SCN is activated and inhibits the 
sympathetic premotor neurons of the PVN, which is the main descending 
autonomous nucleus of the hypothalamus (Figure 2) (158). The activation 
results in a reduced oculosympathetic outflow from the PVN, and the pupils 
constrict. At the same time, connections to the LC activate the premotor 
sympathetic neurons of the LC, working to redilate the pupils. The PVN is, 
like the LC, also involved in pain modulation, and a recent animal study 
showed that the PVN sends descending projections to the caudal spinal 
trigeminal nucleus, which receives trigeminal sensory input (160). These 
projections were bilateral, but with a clear ipsilateral predominance, and most 
of them projected to the ophthalmic area (V1) of the trigeminal nucleus. 
Stimulation of PVN reduces pain, and lesions of the PVN facilitates pain at 
the spinal level (161), and there is reason to believe that it modulates 
trigeminal pain the same way.  
10.3 A central theory emerges 
We propose a central hypothesis for CH pathophysiology involving both the 
SCN, LC and the PVN. We know that activation of the SCN will inhibit the 
premotor sympathetic activity of the PVN, causing reduced oculosympathetic 
outflow to the pupils. In addition, the downregulation of the PVN may result in 
reduced inhibition of incoming trigeminal somatosensory inflow from the 
spinal trigeminal nucleus, causing a bilateral, but predominantly ipsilateral, 
disposition to trigeminal pain. In other words, we propose that the PVN may 
be involved in the initiation of attacks, introducing pain and central 
oculosympathetic dysfunction.  
Further, the trigeminoparasympathetic reflex is activated, causing 
parasympathetic efflux and cerebral vasodilation. The following unilateral 
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vasodilation of the ICA through the osseous carotid canal may reinforce the 
subtle central oculosympathetic dysfunction, creating an ipsilateral third-order 
oculosympathetic dysfunction on top of an already reduced central 
sympathetic outflow from the PVN. This may explain why minor changes in 
the vessel wall could cause a Horner-like syndrome, and why results from 
pupillometric studies have been conflicting.  
Finally, the attacks may be terminated by the LC, which reduces trigeminal 
firing, inhibits cranial parasympathetic output and increases oculosympathetic 
output. In conclusion, we hypothesize that CH represents a condition where a 
permanent or transient downregulation of the PVN activity is compensated 
for by an upregulation of the LC activity.  
This hypothesis is of course highly speculative, and based on observations 
made in very different settings. To test the hypothesis one would have to 
observe the different nuclei simultaneously in the same context, preferably in 
an animal model. However, it is compatible with previous pathophysiological 















11  Conclusions 
This thesis shows that CH patients living in the Arctic region of Norway 
exhibit the same periodicity of headache as CH populations in other 
geographical areas. It also shows that a high share of CH patients suffer from 
sleep disturbances, confirming insomnia as an integral part of the CH clinical 
spectrum. Sleep disturbances may be even more frequent in CH than in 
other primary headaches. Sleep is the single most important trigger of 
headache attacks.  
In addition, the frequency of shift work occupation is high in our CH 
population, suggesting that shift work occupation may facilitate CH in 
predisposed individuals. This may be caused by a circadian misalignment to 
the internal biological clock.  
We found no difference in PER3 clock gene VNTR polymorphisms or 
chronotypes in CH patients compared to controls. The SCN may still be 
involved in the initiation or predisposition of attacks, either by normal 
fluctuations in SCN that cause abnormal responses in the hypothalamic 
nuclei influenced by SCN activity, or by abnormal activity in the SCN itself. 
So far, no evidence of diverting circadian period in CH patients has been 
produced, measured by chronotype or clock gene polymorphism.  
The autonomic nervous system may be more involved the initiation of CH 
attacks than previously assumed, as reduced sympathetically derived 
descending inhibition of nociceptive influx from the 1st branch of the 
trigeminal nerve may facilitate attacks. Our studies document reduced 
parasympathetic activity in remission phase, proving that the pathology of the 
disease is present even though the patient does not experience any 
symptoms. The results also suggest a central origin of the disease, and we 





12  The need for further research 
The role of the SCN in CH pathophysiology is still uncertain, and should be 
studied further. Future studies should focus on the intercept between the 
clock, sleep and the autonomous nervous system, as these all seem to be 
involved in CH pathology. Studies of circadian rhythmicity in CH patients 
should be carried out in laboratory settings, where external zeitgebers can be 
controlled.  
Prospective studies on periodicity of headache and sleep disturbances 
should be sought, and fluctuations of the autonomic nervous system through 
the CH cycle (active bout and remission phase) should be studied. Larger, 
more complex studies on clock genes are warranted, studying multiple genes 
or even Genome Wide Association Studies.  
So far, no suitable animal model has been produced in CH. A preclinical 
animal model of TACs has recently been proposed (162), but it remains to be 
proven that this model works and that it truly represents a human CH 
equivalent. Further endeavors to develop an animal model are welcome, as 
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A Norwegain Cluster headache survey 
 
SPØRRESKJEMA                                    
           
                   Løpenummer:                                                                                                                         



















JEG KAN TENKE MEG EN POLIKLINISK TIME FOR GJENNOMGANG AV MIN SYKDOM, OG 
EVENT. BLODPRØVE, ULTRALYDUNDERSØKELSE AV ØYNE OG PUPILLOMETRI (timen 
er selvsagt gratis)  
                   □ Ja      □ Nei     
 
JEG HAR BODD I NORD-NORGE I MER ENN ETT ÅR 
 




KAN DU SENERE TENKE DEG Å REGISTRERE CLUSTER-ANFALLENE I EN 
HODEPINEDAGBOK SAMMENHENGENDE I 12 MÅNEDER (dersom det blir aktuelt)  
 
     □ Ja      □ Nei     
 2 
A.  PERSONOPPLYSNINGER 
_________________________________________________________________ 
1. SIVIL STATUS 
 




Hvilken utdannelse er den høyeste du har gjennomført? 
 
□ Grunnskole (inkludert framhaldskole, folkehøyskole)   
□ Videregående skole (inkludert realskole, middelskole, yrkesskole, artium, gymnas)  





Yrke:___________________________________  Stillingsandel i %:__________ 
 
b)  
□ Tungt fysisk arbeid  □ Stressende  □ Verken stressende eller tungt fysisk   
 
c) 




a) Mottar du trygdeytelser nå?    
 
□ Ja  □ Nei 
 
Hvis Ja, hvilke trygdeytelser mottar du? 
 
□Sykepenger         □Rehabiliteringspenger     □Attføring    □Uføretrygd    □Annet   
 
Hvis annet, hva da?..................................................................................................................... 
 
b) Er clusterhodepinen årsak til at du mottar trygd? 
   





Nåværende vekt (kg).:_____________ og  
 
høyde (cm) ______________ 
 
Øyefarge:  □ Brun    □ Grønn  □ Annen farge   
 
6. CLUSTERHODEPINE I FAMILIEN                                                                                                                                                                  
 
  □ Ja   □ Nei    Hvis ja, hvem? (mor, far etc..):  ……………………………  
 
7. MIGRENE I FAMILIEN                                                                                                                                                                  
 
  □ Ja   □ Nei                Hvis ja, hvem? (mor, far etc..):  …………………………… 
 
8. EGNE PLAGER 
 
a) Alder da din clusterhodepine debuterte?:  __________________ 
 
b) Alder da din clusterhodepine ble diagnostisert? ___________________ 
 
c) Har du annen type hodepine: 
  
 □ Nei   □ Migrene   □ Annen type 
 
Hvis annen type, vet du hvilken?   
……………………………………………………………….. 
 
d) Dersom du drikker noe kaldt eller spiser iskrem raskt, får du da intens kortvarig hodepine 
(”hjernefrys”)?  
 
□ Nei    □ Har opplevd det   □ Får det ofte 
 
Minner ”hjernefrysen” om din clusterhodepine når det gjelder smertekarakter? 
 
□ Ja   □ Nei □ Uaktuelt 
 
e) Har du annen sykdom?     
 
□ Hatt hjerneslag  □ Bihuleplager □ Høyt blodtrykk   □ Allergi   □ Annen sykdom    
 








a) Opplever du deg selv som ”en stresset type”?  
 
□ Ja   □ Nei                     
  
b) Opplever du deg selv som ”A” eller ”B” menneske?  
 
□ A   □ B      □ Vet ikke               
 
c) Har du det siste året hatt søvnproblemer?  
 
□ Ja   □ Nei                     
 
Hvis ja, skyldes søvnproblemene dine clusterhodepinen?    
 
□ Ja   □ Nei      □ Vet ikke                             
 
d) Har du minst 3 ganger per uke, og i mer enn 1 måned, hatt problemer med å sovne inn 
og/eller vansker med å holde søvnen ved like? 
 
□ Ja   □ Nei                     
 
e) Medfører søvnproblemene tretthet eller prestasjonsproblemer på dagen? 
 
□ Ja   □ Nei                     
 
f) Er søvnproblemene dine mindre eller større i årets lyse måneder? 
 
□ Ingen forskjell  □ Mindre  □ Større    □ Ikke relevant   
 
g) Hender det at du våkner om natten av clusterhodepinen? 
 




a) Røyker du?:  □ Nei   □ Ja    □ Gjorde det tidligere                 
 
b) Hvor mye alkohol tror du at du drikker i forhold til dine jevnaldrende: 
 
□ Mindre enn gjennomsnittet           
□ Gjennomsnittlig             
□ Mer enn gjennomsnittet       
□ Drikker ikke alkohol 
 
c) Har du noen gang forsøkt narkotiske stoffer?:   □ Nei     □ Ja   
 5 
B.  ANFALLSBESKRIVELSE OG BEHANDLING 
_________________________________________________________________ 
1. UTLØSENDE FAKTORER 
 
a) I perioder med clusterhodepine, utløses da anfall av alkohol? 
 
□ Nei       □ Ja      □ Vet ikke                  
 
b) I perioder med clusterhodepine, utløses da anfall av søvn? 
 
□ Nei       □ Ja       □ Vet ikke                 
 
c) I perioder med clusterhodepine, utløses da anfall av liggende stilling? 
 
□ Nei       □ Ja         □ Vet ikke               
 





a) Opplever du forut for clusterhodepine, dvs. mindre enn 1 time før hodepinen, ett eller flere 
av de symptomene som er nevnt nedenfor? 
 
Synsforstyrrelse, prikking/nummenhet i ansikt/armer/bein, problemer med å finne ord/snakke, 
lammelser. 
 
□ Nei  □ Ja     Hvis ja, sett ring rundt de aktuelle symptomer.            
 
b) Hvis ja, hvor ofte opplever du dette i forbindelse med hodepine?   
 
□ Alle anfall  □ Over 50% av anfallene  □ Under 50% av anfallene    □ Sjeldent         
 
c) Hvor ofte har du opplevd dette uten at det har kommet noen påfølgende hodepine? 
 




a) På hvilen side har du clusterhodepine? 
 
□ Venstre  □ Høyre                   
 
b) Kan hodepinen skifte side? 
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□ Nei  □ Ja 
 
c) Har du smalere øyespalte på den siden du pleier å ha vondt? 
 
□ Nei  □ Ja, under anfall  □ Ja, hele tiden                   
 
d) Har du mindre pupille på den siden du pleier å ha vondt? 
 
□ Nei  □ Ja, under anfall  □ Ja, hele tiden                   
 
e) Hvor lenge pleier hodepinen å vare (ca hvor mange minutter i snitt):_________________ 
 
f) Hvor intens er hodepinen? 
 
□ Mild   □ Moderat   □ Intens 
 
g) Hvordan vil du beskrive din hodepine? 
 
□ Bankende  □ Trykkende  □ Stikkende  □ Borende  □ Skjærende 
 
4. LEDSAGENDE SYMPTOMER 
 
a) Under anfall, blir du (det kan settes 2 kryss): 
 
□ Rastløs (må bevege deg)  
□ Bevegelseshemmet (må sitte/ligge helt i ro)  
□ Det er spesielt ille å ligge horisontalt 
 
b) Ledsages hodepinen av:   
 
□ rødt øye □ renning fra øyet □ renning fra nesen □ ingen av delene 
 
Hvor ofte ledsages hodepinen av dette? 
 
□ Alle anfall □ Over 50 % av anfallene □ Under 50 % av anfallene □ Sjeldent  
 
c) Ledsages hodepinen av:   
 
□ ensidig rødme i ansiktet   
□ tørrhet i én ansiktshalvdel  
□ ensidig bleket i ansiktet  
□ ensidig svette i pannen  
□ ingen av delene  
 
Hvor ofte ledsages hodepinen av dette? 
 




d) Ledsages hodepinen av:   
□ kvalme/oppkast   □ overfølsomhet for lyd   □ overfølsomhet for lys  
 
Hvor ofte ledsages hodepinen av dette? 
□ Alle anfall □ Over 50 % av anfallene □ Under 50 % av anfallene □ Sjeldent  
 
e) Ledsages hodepinen av:   
□ generell svette/frostri   □ rask puls   □ langsom puls   □ annet   □ ingen av delene 
 






a) Benytter du ved anfall noen medisin?(Sett ring rundt medikamentet): 
 
□Ingen   
□Imigran (tbl)/ Sumatriptan (tbl)/ Zomig/ Imigran (sprøyter)/ Sumatriptan (sprøyter))/   
Naramig/ Maxalt/ Relpax/ Almogran/  
□Oksygen     
□Annet     
 




b) På en skala fra 0-10 (0=ingen effekt og 10=fullstendig symptomlindring) hvor bra virker 
anfallsbehandlingen?______________ 
 
c) Benytter du forebyggende behandling mot clusterhodepine?: 
 
□ Ingen    □ Verapamil/Isoptin         □ Prednisolon        □ Lithium        □ Annet  
 




d) Hvor lenge benytter du forebyggende behandling? 
 
□ Hele tiden   □ Kun i perioder med clusterhodepine 
 
e) På en skala fra 0-10 (0=ingen effekt og 10=fullstendig symptomlindring); hvor bra virker 











a) Hvor hyppig har du clusterperioder? 
  
□ > 2 per år    
□ 1 per år   
□ < 1 per år   ’ 
□ < 1 per 2 år   
□ Vet ikke da jeg kun har opplevd ≤ 2 perioder 
 
b) Opplever du at clusterperiodene dine kommer med regelmessige intervaller? 
  
□ Nei  □ Ja 
 
c) Kommer clusterperiodene i spesielle årstider? 
 
□ Nei           □ Sommer   □ Vinter  □ Vår    □ Høst 
 
d) Opplever du at clusteranfall kan utløses av sterkt lys? 
 
□ Alle anfall □ Over 50 % av anfallene □ Under 50 % av anfallene □ Sjelden □ Nei, aldri 
 
e) Hvor lenge varer vanligvis en clusterperiode (i uker)?_______________ 
 
f) I hvilken måned starter clusteranfallene?__________ □ Ingen fast måned 
 
g) Er clusteranfallene mer intense i noen av årstidene? 
 
□ Nei           □ Sommer   □ Vinter  □ Vår    □ Høst 
 
h) Er du overfølsom for lys når du ikke har clusterhodepine? 
 
□ Nei           □ Ja, mellom anfallene i en clusterperiode   
□ Ja, både mellom anfallene i en clusterperiode, men også i rolige perioder 
 
i) Bruker du solbriller for å unngå ubehag av sollys? 
 
□ Nei           □ Ja, store deler av året   □ Ja, men bare i den lyse årstiden  
□ Ja, bare i perioder med clusterhodepine     
 
j) Bruker du solbriller for å unngå at clusterhodepine inntreffer? 
□ Nei           □ Ja, store deler av året   □ Ja, men bare i den lyse årstiden  





a) Hvor ofte har du anfall i løpet av ett døgn (gjennomsnitt) i periodene med clusterhodepine? 
 
□ x1   □ x2   □ x3-8   □> x8   
 
b) Har/hadde clusteranfallene dine en tendens til å komme på samme tidspunkt på dagen? 
 
□ Nei   □ Ja        □ Ja, men bare før jeg startet med behandling      
 
c) Hvis ja, når? 
 
□ kl.08-12 □ kl.12-16 □ kl.16-20 □ kl.20-24 □ kl.00-04  □ kl.04-08     
 
d) Kommer anfall mens du sover? 
 
□ Alltid  □ Ofte   □ Sjeldent   □ Aldri       
 
e) Hva synes du er mest korrekt i ditt tilfelle?: 
 
□ Søvn utløser anfall    
□ Mangel på søvn utløser anfall     
 □ Det å ligge flatt utløser anfall   
□ Det er ingen sammenheng mellom leie, søvn og anfall        
 
 
f) Er du fornøyd med den behandlingen du har fått av fastlegen? 
 
□ Ja        □ Nei  
 
Hvis nei, hva var du misfornøyd med hos fastlegen? 
 
□ Det tok for lang tid før diagnosen ble stillet  
□ Jeg behandlet med medisin for annen sykdom    
□ Medisinen var riktig, men den virket ikke på meg  
□ Det tok for lang tid før jeg kom inn til time hos fastlegen   
□ Fastlegen kunne for lite om sykdommen                              
                            
 
g) Er du fornøyd med den behandlingen du har fått av spesialister ved nevrologisk avdeling?  
 
□ Ja        □ Nei  
 
Hvis nei, hva var du misfornøyd med hos nevrolog? 
 
□ Det tok for lang tid før diagnosen ble stillet  
□ Jeg behandlet med medisin for annen sykdom    
□ Medisinen var riktig, men den virket ikke på meg  
□ Det tok for lang tid før jeg kom inn til time hos nevrologen  
□ Nevrologen kunne for lite om sykdommen                              
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□ Jeg har ikke vært hos nevrolog   
                           
h) Er du fornøyd med den behandlingen du har fått av andre spesialister? Angi hvilke ______  
 
□ Ja        □ Nei  
 
Hvis nei, hva var du misfornøyd med? 
 
□ Det tok for lang tid før diagnosen ble stillet  
□ Jeg behandlet med medisin for annen sykdom    
□ Medisinen var riktig, men den virket ikke på meg  
□ Det tok for lang tid før jeg kom inn til time hos spesialisten  
□ Spesialisten kunne for lite om sykdommen                              
                            
 
g) Hvor lang tid tok det fra du fikk diagnosen til du fikk en behandling som virket effektivt?  
 
□ Antall måneder ____________        □ Jeg er enda ikke fornøyd med behandlingen 
 
i) Har du forsøkt alternativ behandling mot clusterhodepine?  
 
□ Nei  □ Akupunktur      □ Homeopati □ Kiropraktorbehandling  
 
□ Manuell terapi □ Annen alternativ behandling, angi: _________________       
 
j) Hvordan virket den alternative behandlingen? (presiser hvilken behandling det gjelder 
dersom du har forsøkt flere behandlinger)  
 
Behandling 1 (angi hvilken)_________________ 
 
□ Ingen endring    □ Clusterhodepinen ble mer intens      
□ Clusterperioden ble lenger   □ Clusterperioden ble kortere  
□ Clusterhodepinen ble mindre intens □ Annet, angi ___________________ 
 
 
Behandling 2 (angi hvilken)_________________ 
 
□ Ingen endring    □ Clusterhodepinen ble mer intens      
□ Clusterperioden ble lenger   □ Clusterperioden ble kortere  
□ Clusterhodepinen ble mindre intens □ Annet, angi ___________________ 
 
 
      
      
 




The Horne-Östberg Morningness-Eveningness Questionnaire 
 
Instruksjon: Les hvert spørsmål nøye før du svarer. Svar på alle spørsmålene i den rekkefølgen 
de står i skjemaet. Hvert spørsmål skal besvares uavhengig av de andre. IKKE gå tilbake for å 
sjekke hva du har svart. Alle spørsmålene har bestemte svaralternativer. Sett bare ETT svar for 
hvert spørsmål ved å sette et kryss ved et av alternativene. Noen spørsmål har en skala 
istedenfor et sett av svaralternativer. På disse svarer du ved å sette et kryss på det passende 
stedet på skalaen. Svar så ærlig som mulig på hvert spørsmål. Både dine svar og resultater blir 
behandlet konfidensielt.  
 
1.  Hvis du bare tenker på den rytmen som er best for deg, på hvilket tidspunkt ville du stått opp dersom du 
var helt fri til å planlegge dagen din? 
          
                 
                               
 0500   0600   0700   0800   0900   1000   1100   1200 




Hvis du bare tenker på den rytmen som er best for deg, på hvilket tidspunkt ville du lagt deg dersom du 
var helt fri til å planlegge kvelden din? 
          
                 
                               
 2000   2100   2200   2300   2400   0100   0200   0300 




I hvilken grad er du avhengig av en 
vekkerklokke om morgenen hvis du må stå 
opp til et bestemt tidspunkt? 
  

















Forutsatt at omstendighetene er gode, hvor 
lett synes du det er å stå opp om morgenene? 
  
Ikke lett i det hele tatt 
















Hvor våken føler du deg i løpet av den første 
halvtimen etter at du har våknet om 
morgenene? 
  

















Hvordan er appetitten din i løpet av den første 




















Hvor trøtt føler du deg i løpet av den første 

















      
8. I forhold til din vanlige leggetid, når legger du 
deg hvis du ikke har noen forpliktelser neste 
dag? 
Sjelden eller aldri senere 
Mindre enn en time senere 
1-2 timer senere 












Du har bestemt deg for å trene. En venn forslår 
at dere skal trene en time to ganger i uken og 
det beste tidspunktet for ham er mellom 0700 
og 0800. Hvis du bare tenker på den rytmen 
som er best for deg, hvordan tror du dine 
prestasjoner vil bli? 
  
Ville vært i god form 
Ville vært i brukbar form 
Ville synes det var vanskelig 















På hvilket tidspunkt om kvelden føler du deg trøtt og derfor trenger å sove? 
          
                 
                               
 2000   2100   2200   2300   2400   0100   0200   0300 




Du ønsker å være i toppform for en test som 
du vet kommer til å være mentalt krevende og 
som vil vare i to timer. Du er helt fri til å 
planlegge dagen din. Dersom du bare tar 
hensyn til den rytmen som er best for deg 




















Hvis du la deg klokken 2300 hvor trøtt ville du 
da vært? 
  

















Av en eller annen grunn har du lagt deg flere 
timer senere enn vanlig. Du trenger ikke stå 
opp til en bestemt tid neste morgen. HVILKEN 
av de følgende hendelsene vil du med størst 
sannsynlighet oppleve? 
  
Ville våknet til vanlig tid UTEN å sovne igjen 
Ville våknet til vanlig tid og så halvsove 
Ville våknet til vanlig tid, men så sovnet igjen 














En natt må du være våken mellom 0400 og 
0600 for å være nattevakt. Du har ingen avtaler 
neste dag. HVILKET av de følgende 
alternativer passer deg best? 
  
Ville IKKE sovet før nattevakten var over 
Ville tatt en blund før og sovet etterpå 
Ville sovnet mye før og en blund etterpå 














Du må gjøre to timers hardt fysisk arbeid. Du 
kan planlegge dagen din helt fritt. Med tanke 
på rytmen som er best for deg HVILKET 
























Du har bestemt deg for å hardtrene. En venn 
forslår at dere skal trene en time to ganger i 
uken og det beste tidspunktet for ham er 
mellom 2200 og 2300. Hvis du bare tenker på 
den rytmen som er best for deg, hvordan tror 
du dine prestasjoner vil bli? 
  
Ville vært i god form 
Ville vært i brukbar form 
Ville synes det var vanskelig 















Anta at du kan velge din egen arbeidstid, at du jobber 5 timer dagen (inkludert pauser), at jobben var 
interessant og gav resultater. Hvilke FEM SAMMENHENGENDE TIMER ville du valgt (sett kryss i 5 
sammenhengende ruter) 
                          
 24 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 




Når på dagen føler du deg best? (sett kryss i en rute)  
                          
 24 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 




Man hører om A-mennesker (morgenfugler) og 
B-mennesker (kveldsmennesker). HVILKEN av 
disse typene vil du si at du er? 
  
Helt klart A-menneske 
Heller et A- enn et B-menneske 
Heller et B- enn et A-menneske 

































Referanse: Horne, J. A., & Östber, O. (1976). A self-assessment questionnaire to determine morningness-eveningness in human circadian 
rhythms. International Journal of Chronobiology, 4, 97-110. Til norsk ved Idalill Udnes, Toril Johanse, Tom Lilleholt og Ståle Pallesen. 
PSQI 
 
Instruksjoner: Følgende spørsmål har med ditt vanlige søvnmønster den siste måneden å 
gjøre. Du skal svare på hva som er mest riktig for de fleste dager og netter den siste 
måneden. Vennligst svar på alle spørsmål. 
 
1. I løpet av den siste måneden, når har du vanligvis lagt deg om kvelden? 
VANLIG LEGGETID_____________ 
 




3. I løpet av den siste måneden, når har du vanligvis stått opp om morgenen? 
VANLIGVIS  STÅTT OPP KL_________ 
 
4. I løpet av den siste måneden, hvor mange timer søvnhar du faktisk fått om natten? (Dette 
kan være forskjellig fra hvor mange timer du oppholdt deg i sengen.) 
ANTALL TIMER SØVN HVER NATT ___________ 
 
 
For hvert av de følgende spørsmål, kryss av for det beste svar. Vennligst svar på alle 
spørsmålene. 
 
5. I løpet av den siste måneden, hvor ofte har du hatt problemer med søvnen fordi du… 
 
(a) Ikke klarer å sovne i løpet av 30 minutter 
   Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
   siste måneden___       en gang i uken___   ganger i uk n___    ganger i uken___  
 
 (b) Våkner opp midt på natten eller tidlig om morgenen 
Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    siste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 
 (c) Må opp for å gå på toalettet 
Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    s iste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 
(d) Ikke klarer å puste ordentlig 
Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    s iste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 
(e) Hoster eller snorker høyt 
Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    s iste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 
(f) Føler deg for kald 
 Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
  s iste måneden___       en gang i uken___   ganger i uk n___    ganger i uken___   
 
(g) Føler deg for varm 
Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    s iste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 
 (h) Har vonde drømmer 
Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    s iste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 
 (i) Har smerter 
 Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    s iste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 




 Hvor ofte, i løpet av den siste måneden, har du hatt problemer med søvnen på grunn av dette 
 Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    s iste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 
6. I løpet av den siste måneden, hvordan vil du bedømme søvnkvaliteten din totalt sett? 
Veldig bra    _____          
Ganske bra    _____         
Ganske dårlig  _____   
Veldig dårlig  _____    
 
7. I løpet av den siste måneden, hvor ofte har du tatt medisin (med eller uten resept) som 
hjelp til å sove? 
Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    s iste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 
8. I løpet av den siste måneden, hvor ofte har du hatt problemer med å holde deg våken 
under bilkjøring, måltider eller når du holder på med sosiale aktiviteter? 
Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    s iste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 
9. I løpet av den siste måneden, hvor stort problem har det vært for deg å ha overskudd nok 
til å få ting gjort? 
Ikke noe problem i det hele tatt  _____   
Bare et lite problem                    _____   
Et visst problem                       _____       
Et stort problem                          _____ 
 
 
10.  Deler du seng eller rom med noen? 
Deler ikke seng eller rom med noen                 _____          
 Partner/romkamerat i annet rom                    _____       
 Partner i samme rom, men ikke i samme seng    _____  
 Partner i samme seng                                          _____         
 
Hvis du har en partner eller romkamerat, spør han/henne hvor ofte i løpet av den siste 
måneden du har hatt… 
 
(a) høy snorking 
Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    s iste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 
(b) lange pustestopp under søvnen 
Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    s iste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 
(c) rykninger eller sammentrekninger i beina under søvnen 
Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    s iste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 
(d) episoder med desorientering eller forvirring under søvnen 
Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 
    s iste måneden___       en gang i uken___   ganger i uken___    ganger i uken___  
 
(e) annen type uro under søvnen; vennligst beskriv______________________________ 
______________________________________________________________________ 
Ikke i løpet av den       Mindre enn         En eller to         Tre eller flere 


















Pittsburgh Sleep Quality Index 
(Buysse, Reynolds III, Monk, Berman & Kupfer, 1989) 
Til norsk ved Petter Franer, Inger Hilde Nordhus, Ståle Pallesen og Simen Øverland 
